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“Since we cannot know all that there is to be known about anything,
we ought to know a little about everything”
Blaise Pascal
“We are unconscious of most of our body’s processes, thank goodness, 
because we’d screw it up if we weren’t. 
The human body is so complex, with so many parts...
 The idea that we are consciously caretaking 
 a large and mysterious system is ludicrous.”
Lynn Margulis
ABSTRACT
The role of the human gut microbiota in impacting host’s health has been widely  studied in the last 
decade. Notably, it  has been recently  demonstrated that diet  and nutritional status are among the 
most important modifiable determinants of human health, through a plethora of presumptive 
mechanisms among which microbiota-mediated processes are thought to have a relevant role.
At present, probiotics and prebiotics represent a useful dietary  approach for influencing the 
composition and activity of the human gut microbial community. 
The present study is composed of two main sections, aimed at elucidating the probiotic potential of 
the yeast strain K. marxianus B0399, as well as the promising putative prebiotic activity ascribable 
to four different flours, naturally enriched in dietary fibres content.
Here, by in vitro studies we demonstrated that  K. marxianus B0399 possesses a number of 
beneficial and strain-specific properties desirable for a microorganism considered for application as 
a probiotics. Successively, we investigated the impact of a novel probiotic yoghurt containing B. 
animalis subsp. lactis Bb12 and K. marxianus B0399 on the gut microbiota of a cohort of subjects 
suffering from IBS and enrolled in a in vivo clinical study. We demonstrated that beneficial effects 
described for the probiotic yoghurt were not associated to significant modifications of the human 
intestinal microbiota. 
Additionally, using a colonic model system we investigated the impact of different flours 
(wholegrain rye and wheat, chickpeas and lentils 50:50, and barley milled grains) on the intestinal 
microbiota composition and metabolomic output, combining molecular and cellular analysis with a 
NMR metabolomics approach. We demonstrated that each tested flour showed peculiar and positive 
modulations of the intestinal microbiota composition and its small molecule metabolome, thus 
supporting the utilisation of these ingredients in the development of a variety of potentially 
prebiotic food products aimed at improving human health.
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FROM METCHNIKOFF 
TO THE NEXT GENERATION  SEQUENCING: 
HOW THE UNDERSTANDING OF “THE MICROBIAL 
WORLD WITHIN US” IS CHANGING
1
Human gut microbiota: what is it?
Human beings are colonised by several 
microbial communities, which have the 
potential to impact on the host’s health. 
Different human districts, such as skin, 
mouth, vagina, airways and gastrointestinal 
tract (GIT), harbour specific bacterial 
ecosystems. Anatomically, the human GIT is 
divided into six sections, the oral cavity, 
oesophagus, stomach, small intestine 
(duodenum, jejunum and ileum), the colon 
or distal gut (ascending, transverse and 
descending colons) and rectum (Fig. 1). 
Each GIT section is characterised by a 
specific microbial community, which to 
some extent  reflects the physiology and the 
dynamics of that compartment. The number 
of microbes in each niche increases as one 
moves from the stomach to the rectum 
resulting in one of the most densely 
populated ecosystems being found in the 
distal gut or colon. Indeed, the most rich and 
complex microbial consortium resides in the 
colon, reaching a bacterial concentration of 
100-200 billions of cells/gram of faeces, so 
that the number of microbial inhabitants 
within the gut lumen can achieve 1014 
(Marchesi et al., 2010; Marchesi et al., 2011; 
van den Bogert et al., 2011). Even if the 
human intestinal microbiota is one of the 
most dense ly  popula ted microbia l 
ecosystems in nature, sequence-based 
analysis demonstrated that it is characterized 
by a peculiarly  low phylogenetic diversity 
(Fig. 2).
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Figure 1. The anatomy of the gastrointestinal tract, major bacterial phyla and their 
abundance in each niche. (from Marchesi et al., 2011)
Figure  2. Comparison of microbial diversity in the human colon against other 
deeply studied animal and environmental ecosystems. Percent representation of 
divisions in each environment is reported by Ley and colleagues (2006). 
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Out of the over 70 phyla described to date, Next Generation Sequencing (NGS)-based survey 
indicated that 6 to 10 is the number of bacterial phyla per individual represented in the gut 
microbiota: Acidobacteria, Actinobacteria, Bacteroidetes, Firmicutes, Fusobacteria, 
Lentisphaerae, Proteobacteria, candidate division TM7, Verrucomicrobia and Deniococcus-
Thermus (Marchesi et al., 2010; 2011). Among these, Firmicutes and Bacteroidetes represent 
up to 90% of the intestinal microbiota, with a relative abundance of approximately 65% and 
25%, respectively (Fig. 3). 
A great diversity at lower taxonomic levels and a considerable inter-individual variability in 
the bacterial species and strains have been described. In fact, the number of species have been 
estimated to range in the hundreds (Qin et al., 2010) and a bloom at phylotype level have been 
reported, with about 16,000 phylotypes estimated to thrive in the human intestine (Peterson et 
al., 2008). A consequence of this phylotypes diversity is that phylogenetic trees of the gut tent 
to have few branches, which are not deep, but have a large degree of radiance at the ends (Fig. 
4). Interestingly, 70% of these phylotypes are subject-specific, none of which is present at 
more than about 0.5% abundance in all subjects. Furthermore, metagenomics studies 
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Figure  3. Relative proportion of the 
phylotypes belonging to the 8 main 
bacterial divisions which have been 
found in the human gut microbiota, out 
of the over 70 globally known (Candela 
et al., 2010).
demonstrated that about 65% bacteria identified in the intestinal microbiota were previously 
unknown, and among them 80% were uncultivable (Turnbaugh et al., 2009).
While studies looking to define the core microbiota have focused on describing the Bacteria 
within the human gut microbiota, a significant number of Archaea is populating this 
ecological niche. The most common species found in the distal gut come from the 
Euryarchaeota and in particular the Methanobacteriaceae family (Scanlan et  al., 2008; Dridi 
et al., 2009) with Methanobrevibacter smithii and Methanosphaera stadtmanae the two 
predominant inhabitants. However, other rarer archaeal sequences that cluster in the 
Methanosarcinales (Scanlan et al., 2008), Halobacteriaceae (Oxley et al., 2010) and a 
putative sixth archaeal order (Mihajlovski et al., 2008; 2010) have been reported. 
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Figure 4. Phylogenetic tree representing the groups of bacteria most frequently 
detected in human faeces using 16S rRNA gene sequencing. The extent of the 
bold areas indicate diversity and abundance of the bacterial groups. The 
phylogenetic tree is reported by Vrieze and colleagues (2010). 
Nevertheless, in all studies to date M. smithii and M. stadtmanae are the two main Archaea 
(Dridi et al., 2011), whilst  it is still unclear to what extent the much rarer species are 
autochthonous or are actually  contaminants from our diet/environment (Marchesi et al., 
2011).
The gut microbiota additionally  contains subdominant micro-eukaryotic and viral components 
that can interact with symbiotic bacteria to play a primary role in both ecosystem structure 
and function. Most of the researches undertaken on the eukaryotic members of the gut 
ecosystem have been culture-based approaches targeting fungal diversity (Candida and 
Saccharomyces spp.). Only recently culture-independent approaches looking at the micro-
eukaryotic fraction of the human gut microbiota have been applied (Scanlan and Marchesi, 
2008). The micro-eukaryotic diversity and concentration are several orders of magnitude 
lower than the bacterial ones. 18S rRNA gene-based methods have been used, demonstrating 
that the genus Blastocystis and Ascomycota were the predominant micro-eukaryotes 
populating the intestinal ecosystem (Scanlan and Marchesi, 2008), whilst  yeast are rarely 
obtained. Indeed, it has been proposed that the micro-eukaryotic fraction of the intestinal 
microbiota might have a significant role only in presence of a dysbiosis (Goldman and 
Huffnagle, 2009). Dysbiosis has not only been associated to yeast and micro-eukaryotic cells, 
but Lepage and colleagues (2008) have hypothesized a role for distal gut bacteriophages as 
driver of dysbiosis in the distal gut leading to IBD. Very recently, Reyes et al. (2010) used a 
NGS approach to study the virome, the collective metagenome of virus-like particles isolated 
from human faecal samples. They demonstrated that 81% of reads generated in the 
metagenomics study  did not match to any known viruses, and that the human virome consists 
of prophages or phages generally classified as temperate (i.e., coliphage P22-like), commonly 
hosted by Firmicutes and Bacteroidetes members.
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Why a human intestinal microbiota?
With ≥100 times as many genes as our 2.85 billion base pair human genome, the collective 
genome of our symbiotic intestinal microbiome endows humans with crucial physiological 
traits that have not been evolved in his own (Gill et al., 2006; Neish, 2009; O'Hara and 
Shanahan, 2006; Xu et al., 2007). These traits are mainly belonging to three functional macro-
categories: protective, structural and metabolic functions (Fig. 5).
The human intestinal microbiota exerts a pivotal contribution to the human energy balance 
and nutrition. Throughout the extension of the host metabolic capacity to indigestible 
polysaccharides, the microbiota has the intrinsic ability  to produce short chain fatty acids 
(SCFAs), which constitute a fundamental energy  source for human colonic epithelium and 
provide from 5 to 15% of the total energy requirement (Neish, 2009; Box n. 1). The intestinal 
microbiota can further affect the absorption of key mineral and can synthesize several 
vitamins involved in different host metabolic pathways, as cobalamin (vitamin B12), pyridoxal 
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Figure 5. The human intestinal microbiota exert several protective, structural and 
metabolic functions on the intestinal mucosa (from O’Hara and Ferguson, 2006).
phosphate (the active form of vitamin B6), pantothenic acid (vitamin B5), niacin (vitamin B3), 
biotin, tetrahydrofolate and vitamin K (Kau et al., 2011). 
Intestinal microorganisms exert a strong impact also on energy storage by interacting with the 
host lipoprotein lipase (LPL)-mediated process for triglyceride storage in adipocytes. In 
particular, throughout the suppression of the intestinal epithelium expression of the LPL-
inhibitor fasting-induced adipose factor (Fiaf), the intestinal microorganisms promote the 
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BOX N. 1 - THE SCFAS PARADIGM
The SCFAs paradigm represents a relevant example of how nutrient processing by 
the human intestinal microbiota and host diet combine to shape immune responses. 
SCFAs are the main end products of the microbial fermentations of plant 
polysaccharides that cannot be digested by  humans, since our genomes do not 
encode the large repertoire of glycoside hydrolases and polysaccharides lyases 
needed to cleave the varied glycosidic linkages present in the dietary  glycans, i.e host 
glycans enclosed in mucus and glycans from plant polysaccharides (xylan-, pectin- 
and arabinose-containing carbohydrate structures) (Qin et al., 2010). Indeed, the 
human intestinal microbiota is endowed with a real arsenal of carbohydrate-active 
enzymes (CAZymes), many  of which are not present in the human glycobiome. The 
percentage of sequences in the gut microbiome assigned to CAZymes is greater than 
all the other KEGG pathways, indicating the abundance and diversity of microbiome 
genes directed towards the metabolism of a wide range of polysaccharides (Candela 
et al., 2010). 
In addition to acting as an energy source for the host, SCFAs exert notable effects on 
host immune responses. Levels of butyrate modify  the cytokine production profile of 
immune competent cells and promote intestinal epithelial barrier integrity, thus leading 
to preventing aberrant inflammatory responses (Jacobs et al., 2009; Kau et al., 2011). 
Recent studies highlighted the importance of the SCFA acetate in preventing infection 
by  the enteropathogenic Escherichia coli (O157:H7) (Fukuda et al., 2011), as well as 
the possibility that SCFAs may  regulate the acetylation of lysine residues, a covalent 
modification which can have a role in innate and adaptive immune responses (Kim et 
al., 2010).
absorption of polysaccharides from the gut lumen (Bäckhed et al., 2004). Moreover, intestinal 
microorganisms are able to increase the glucose uptake in the host intestine and produce a 
substantial elevation in serum glucose and insulin, stimulating the hepatic lipogenesis 
(Delzenne et al., 2011).
The microbiota forms an integral part of the natural mechanisms of mucosal surfaces that 
prevent the organism from pathogenic microorganisms. In physiological conditions, it 
prevents attachment and multiplication of pathogenic or virulent microorganisms on the 
intestinal surfaces, as well as it plays a critical role in avoiding the invasion of these 
microorganisms into epithelial cells and the circulation (Tlaskalová-Hogenová et al., 2011).
Moreover, the fine and dynamic cross-talk between intestinal microorganisms and GIT 
immune system is crucial for its development and homeostasis (Sansonetti and Medzhitov, 
2009). The host-microbe interface is characterized by  the dual necessity to peacefully  coexist 
with symbiotic microorganisms and to quickly respond to the microbial pathogens to which 
we are intermittently exposed. Studies carried out on germ-free mouse models revealed that 
the entire structural development of our GIT depends on the dynamic interaction with the 
intestinal microbiota (Sansonetti and Medzhitov, 2009). In fact, intestinal microorganisms 
educate the host immune system to tolerance against harmless antigens whilst, at  the same 
time, concur in the maintenance of a fast responsiveness towards harmful pathogens. In this 
context, the human intestinal microbiota contributes to the development and function of the 
immune system and it has been demonstrated that germ-free animals have altered 
compositions of CD4+ T cells and IgA-producing B cells in the lamina propria, as well as the 
induction of T-lymphocyte subset is augmented by distinctive species of the luminal 
microbiota (Ashida et al., 2011). In addition, intestinal microorganisms exert a role of primary 
importance in the proper structuring of inductive and effector sites of the host  GIT immune 
system (Garrett et al., 2010).
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Humans and intestinal microbiota: when and how?
Recent technological advancement in the phylogenetic analysis of the microbial communities 
inhabiting the human ecosystems provided a huge number of novel insights about the 
development of the intestinal microbiota during the ageing process (Fig. 6). 
It is still questionable if newborns are sterile and are colonized after birth by environmental 
microbes or if the birth canal, which is heavily colonized by microbes, provide the primary 
inoculum for the baby. From an evolutionary perspective, it is unlikely to be accidental the 
relevant bacterial load in the birth canal, and it  is thought that the vagina has likely  evolved to 
provide the primary inoculum for the newborns (Dominguez-Bello et al., 2011). Indeed, 
recent community-wide metagenomics studies revealed that vaginally  delivered babies 
acquire, at birth, their own mother’s vaginal microbiota. Therefore, neonates’ different body 
sites are colonized with essentially the same microbiota that was inherited vertically from 
their mothers, which is dominated by Lactobacillus and Prevotella spp. (Dominguez-Bello et 
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Figure 6. Diagram of the development of the microbiota from the first inoculum as 
an infant through continued change, modified by diet, genetics and the 
environment, throughout life (from Dominguez-Bello et al., 2011)
al., 2010). After the primary inoculation at birth, infants continue to have multiple exposures 
to human microbes and, only after a not yet well established time frame, babies develop  the 
distinct microbial communities found in each body district in adulthood.
During the ageing process, humans are involved in a complex and dynamic interplay with 
environmental microbes that, after weaning, culminates in the acquisition of an adult-type 
intestinal microbial community  (Palmer et al., 2007; Biagi et al., 2011). In particular, infancy 
is a crucial period of human life, since changes in diet and environment are reflected in 
relevant fluctuations in the GIT microbiota composition. This microbial plasticity providess 
efficient means for adaptation to the changing circumstances of development (Dominguez-
Bello et al., 2011).
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Advantages and limits of the classic 
approaches
Traditional culture-dependent techniques are 
based on selective culturing, morphological, 
biochemical, and physiological assays. This 
array  of microbiological analyses requires 
laborious and time consuming cultivation of 
microorganisms, and allows the recovering 
of less than 20-30% of the total bacterial 
richness because of the insufficient 
anaerobic cultivation technologies, as well 
as the poor knowledge about the specific 
bacterial carbon source requirements (Bik et 
al., 2006). For this reason the vast majority 
of the biodiversity of the human microbiota 
remains uncultured, and the assessment of 
the microbial composition and abundance of 
such a dense and complex microbial 
community  needs to be performed through 
molecular techniques. The mostly used 
molecular marker for genetic diversity  of 
bacteria is the 16S rRNA gene, due to the 
fact that this gene is conserved in all 
eubacteria and present an appropriate 
balance of conservation and variability  to 
allow discrimination between different 
species and strains, as well as identification 
and assignation to particular phylogenetic 
groups (Sekirov et al., 2010). 
The 16S rRNA gene consists of about 1,500 
nucleotides and contains regions conserved 
among all the bacteria, interspersed with 9 
regions (V1 to V9, Fig. 7), which are highly 
variable among bacterial phylotypes (groups 
with 97-99% of sequence identity). 
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Conserved regions can be used as targets for PCR primers with almost-universal bacterial 
specificity. Phylotypes identification is obtained by comparative sequence analysis of the 
amplicons using available databases, as the Ribosomal Database Project (RDP, http://
rdp.cme.msu.edu/). Different 16S rRNA-based techniques are available for the 
characterization of complex bacterial ecosystems (Box n. 2), and the choice of the approach 
depends on the question to be answered. By the use of fingerprinting techniques, as PCR-
Denaturing Gradient Gel Electrophoresis (PCR-DGGE), an approximate “picture” of the most 
abundant bacterial components is obtained, but  these approaches are usually not quantitative. 
Conversely, quantitative PCR (qPCR) and Fluorescent In Situ Hybridization (FISH), can 
quantify one or few bacterial groups targeted by specific primer sets or probes. Recently, 
several phylogenetic microarray platforms have been developed allowing simultaneous 
quantification of many  bacterial components of the targeted ecosystem, even if this approach 
lacks the possibility to discover unknown members. In the last years, the phylogenetic 
characterization of the gut microbiota has greatly  benefit from the combination of these 
approaches. However, none of them can give as accurate information as the most modern 
meta-omics approaches and next generation sequencing techniques.
 
13
Figure 7. Conserved (C1-C9, grey) and hyper-variable (V1-V9, different colours) 
regions in the 16S rRNA gene, from Petrosino et al. (2009).
BOX N. 2 - ADVANTAGES AND LIMITS OF THE MAIN MOLECULAR 
TECHNIQUES FOR THE GUT MICROBIOTA CHARACTERISATION
✴ PCR-based DNA profiling techniques. PCR-based DNA profiling techniques 
include denaturing gradient gel electrophoresis (DGGE), temperature gradient gel 
electrophoresis (TGGE), and terminal-restriction fragment length polymorphism (T-
RFLP). The use of these techniques can provide a quick global assessment of the 
microbiota with a semi-quantitative measurement; however, these techniques are not 
quantitative for population size and are unable to provide detailed information on 
bacterial identities and phylogenic distribution.
✴ Quantitative PCR (qPCR). qPCR is a commonly  used method to perform absolute 
or relative quantification of specific bacterial group in the gut microbiota. qPCR assays 
are  highly sensitive and provide accurate measurements. However, qPCR assays are 
normally  limited to the measurement of one or few target bacterial species per assay 
under the conditions that the target gene sequence of known bacterial groups/species 
must be available in advance. Therefore, the main limitation of qPCR is that an 
individual assay is unable to provide a global assessment of bacterial communities.
✴ Fluorescent in situ hybridization (FISH). Flourescein-labeled oligonucleotide 
probes targeting 16S rRNA are widely  used for the gut microbiota characterization. 
Each probe has its own specificity to recognize a particular group of bacteria. 
Bacterial cells can be visualized by  microscopy or flow cytometry. FISH is a 
quantitative method, which can provide information on the spatial distribution of target 
bacteria in the sample and can detect uncultured bacteria without enrichment. 
However, the sensitivity  of FISH is relatively  low. The sequence of target genes must 
be available in the database and only a few probes can be used at one time.
✴ Phylogenetic DNA microarray. A number of new  DNA phylogenetic microarray 
have been reported in literature, based on 16S rRNA genes and Small-Subunit (SSU) 
rRNA genes. The advantages of microarray  include high-throughput, cost-
effectiveness, direct phylogenetic identification, and speed. However, detection limits, 
cross-hybridization and hybridization biases (i.e., some sequences hybridize more 
readily  than others) are needed to be addressed and optimized when gut microbiota 
microarrays are used. Also, the targets sequences must be known in advance and 
hence it is not possible to identify novel species/strains of bacteria.
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Omics science and the gut microbiota: “United, we stand”
The development of high throughput sequencing techniques and other affordable approaches 
allowing a large-scale analysis of microbial communities resulted in the application of 
‘omics’ technologies, including metagenomics, metatranscriptomics, metaproteomics, and 
metabolomics (Simon and Daniel, 2011). These techniques allow to analyze DNA, mRNA, 
proteins and metabolites of the gut microbiota and then unravel the complex diversity and 
functions within the gut microbial ecosystem.
Metagenomics refers to culture-independent and sequencing-based studies of the collective 
set of genomes of mixed microbial communities (metagenomes), and aims at exploring their 
compositional and functional characteristics (Gill et al., 2006; Petrosino et al., 2009).  Using 
metagenomics, the analysis of large data sets allowed the exploration of the taxonomic and 
functional biodiversity and of the systems biology study of diverse ecosystems, among which 
the gut microbiome.
While in the last decade Sanger sequencing was used to generate data in most microbial 
genomics and metagenomics sequencing projects, NGS technologies have been widely used 
in the last 5 years to study the complex microbial ecosystem populating the GIT. In fact, 
community  structures can now be investigated, bypassing previously needed cloning and 
cultivation procedures, at much lower cost than Sanger sequencing, and at much higher 
resolution by revealing rare or less abundant taxa.
NGS phylogenetic analysis of the gut microbiota is based on the amplification of selected 
target regions of the 16S rRNA genes. In particular, regions V1, V2, V3 and V6 have been 
used for studying the human GIT ecosystem. Two main platforms have been developed for 
NGS studies: i) Genome Sequencer 454 FLX system, that  generally  produces around 400,000 
reads with average lengths of 250-350 bp, a read size sufficient to cover most of the variable 
regions in the 16S rRNA gene; ii) Illumina Genome Analyzer system, that routinely  produces 
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more than ten times the number of reads per run as the 454 FLX system with average lengths 
of 35-75 bp. 
To date, large-scale analyses of genomic and metagenomic sequences have provided gene 
catalogs and statistical evidence on protein families involved in the predominant functions of 
the human gut microbiome (Gill et al. 2006; Flint et al. 2008; Turnbaugh et al. 2009; Qin et 
al. 2010). In particular, functional metagenomics approach provides an experimental proof of 
function to highly prevalent genes and gene clusters of the human gut microbiome. Coupling 
sequence-based and activity-based metagenomics, the entire genetic and metabolic potential 
of the human microbiota are able to answer not only  the “who’s there” question, but also 
“what can they do together?”. 
Metatranscriptomics is based on high-throughput RNA sequencing and can be used to obtain 
functional insights into the gut microbiota as well as information about how environmental 
and host changes induce community-wide alterations in gene expression. RNA-sequencing 
(RNA-Seq) is a major technique used in metatranscriptomics analysis and its application to 
the human intestinal microbiota has been recently described (Gosalbes et al., 2011; Turnbaugh 
et al., 2010). The interest in human gut metatranscriptomics is relevant, because differently 
from metagenomic DNA-based analyses, which cannot differentiate between expressed and 
non-expressed genes, it provides data reflecting the actual metabolic activity  of the 
ecosystem.
Metaproteomics, also referred to as whole community  proteomics, is a new emerging 
function-based approach to identify  key  microbial functions in the community  (Ram et al., 
2005). Non-targeted mass spectrometry (MS)-based shotgun proteomics approach was 
recently  used to detect and identify  the array of proteins contained within the gut 
metaproteome without the need for gel-based separation or de novo sequencing (Verberkmoes 
et al., 2009). The advantages of metaproteomics are the direct monitoring of microbial protein 
16
expression levels and the identification of new functional genes. To date, metaproteomics has 
been successfully used to analyze the complex proteome of the human distal gut microbiota 
(Verberkmoes et al., 2009; Zoetendal et al., 2008).
Metabolomics aims at quantifying all metabolites in a cellular system under defined 
conditions and at different time points so that the dynamics of any biotic, abiotic, or genetic 
perturbation can be accurately assessed. Metabolic profiling studies are mainly adopting MS 
and Nuclear Magnetic Resonance (NMR) spectroscopic platforms to measure the metabolome 
of biological samples.  Indeed, the metabolic composition of fecal extracts provides a potent 
tool for elucidating the complex metabolic interplay between the symbiotic bacterial 
populations, as well as their interaction with the host (Holmes et al., 2011) or their response to 
nutritional intervention (Jacobs et al., 2009). In particular, metabolomics approaches that 
combine NMR profiling with multivariate pattern-recognition techniques are providing a 
holistic view of the perturbations of metabolism in response to diet or disease. NMR-based 
metabolite profiling is a well-established technique producing rapid, robust, and reproducible 
profiles without extensive sample preparation. It is a comprehensive but not very  sensitive 
method (Jacobs et al., 2009). The metabolomics approach has been predominantly applied to 
urine, plasma and faecal extracts, and provides information on the exogenous and endogenous 
metabolism of the host. 
In the next future, the challenge of the scientific community would be to integrate these 
complementary  meta-omics data into an eco-systems biology  approach to study the human 
microbiome.
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Diet and nutritional status are among the 
most important modifiable determinants of 
human health. Recent studies emphasized 
the huge impact of nutrition, which is likely 
to outweigh that of the host genotype 
(Gophna et al., 2011). Diet composition has 
been demonstrated to provoke substantial 
effects on specific groups of bacteria 
constituting the human core microbiome 
(Walker et al., 2011). In particular, diet-
driven modifications occur rapidly, being 
detectable within 1-4 days, and are reversed 
in a comparable time course (Kau et al., 
2011; Walker et al., 2011). Assuming that 
the mean transit colonic time is ranging 
from 48 to 72h (Macfarlane et al., 1998), 
these kinetics appear to be consistent with 
immediate effects of dietary residue upon 
relative bacterial growth rates in the colon.
Very recently, a limited number of 
fascinating  studies have been shedding light 
to the the host-diet-microbiota dynamic 
interplay. Walker et al. (2011) studied the 
diet-dependent microbiota dynamics in 
overweight men subjected to diets 
selectively enriched in main types of 
fermentable carbohydrates. A number of 
fluctuations in response to the different diet 
was demonstrated. Interestingly, the 
individual specificity  of the gut microbiota 
was challenged by diet-driven changes in 
the major bacterial phylotypes. 
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Investigating the impact of long- and short-term dietary impact on the gut microbiota, Wu et 
al. (2011) found that higher fat intake and lower fiber intake are associated with particular 
bacterial groups. The Authors studied the influence of diet on the gut microbiota in the 
context of the enterotypes theory  recently proposed by Arumugam et al. (2011; Box n. 3). 
Notably, enterotypes are determined by long-term dietary  habits. Conversely, short-term 
controlled dietary intervention, whilst modulating rapid and significant modifications to the 
overall asset of our microbial complement within the first 24 h (Walker et al., 2011), did not 
provoked stable changes to the pattern of intestinal microbial populations sufficient to switch 
individuals from an enterotypes to another one.  
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BOX N. 3 - THE ENTEROTYPES OF THE HUMAN GUT MICROBIOME
In 2011, Arumagam et al. performed the first extensive work of annotation of predicted 
gene functions on 22 de novo Sanger-sequenced European gut metagenomes, 
combined with 17 existing Sanger and pyrosequencing gut data sets. These data 
were mapped to 1,511 reference bacterial genomes, including 379 publicly available 
human microbiome genomes generated by  the Human Microbiome Project  and the 
European MetaHIT consortium. The Authors were able to assign 53% of the 
sequenced fragments to a genus and the 80% to a phylum. 
Notably, multidimensional cluster analysis and PCA revealed that samples formed 
three distinct clusters, that the Authors named “enterotypes”. Each of these three 
enterotypes are identifiable by  the variation in the levels of one of three genera: 
Bacteroides (enterotype 1), Prevotella (enterotype 2), and Ruminococcus (enterotype 
3). A functional analysis of the enterotype assets indicated that each enterotype use 
different routes to generate energy  from fermentable substrates available in the colon. 
Enterotypes 1 and 2 were enriched in biosynthesis of vitamins, whereas enterotype 3 
were enriched in membrane transporters, mostly for sugars.
It is noteworthy  that enterotypes do not seem to differ in functional richness, and 
virtually  host properties, i.e. nationality, gender, age or body  mass index, significantly 
correlates with the enterotype. Conversely, functional properties, as host immune 
modulation and other physiological conditions might explain and allow classification of 
human groups into the three enterotypes.
Taken together, the current researches on the response of the intestinal microbiota to diet  lead 
to a dynamic view in which the microbiota is continuously evolving in adaptation to long- and 
short-term dietary habits (Thomas et  al., 2011). Diet may select peculiar differences in the 
intestinal microbiota that are strictly associated to geographical distribution. A comparative 
study between rural children in Burkina Faso (Africa) and Italian children subjected to 
Western lifestyle, showed that the intestinal microbiota of African children was enriched in 
Bacteroidetes and Actinobacteria, and depleted in Firmicutes and Proteobacteria. (De Filippo 
et al., 2010; Fig. 8) The Authors explained this difference by the higher dietary fiber content 
of the rural African diet, mainly composed of cereals, legumes and vegetables, which would 
favor the development of the polysaccharide-degrading Bacteroidetes, provided with an 
arsenal of carbohydrate-active enzymes (CAZymes) useful in acquiring energy from these 
undigestible sources. Furthermore, the types of Bacteroidetes present in the African children's 
microbiome differed from those in typical European microbiomes, as they  may be ideally 
suited to grow on polysaccharides abundant in the Burkina Faso diet, such as xylan or 
cellulose.
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Figure 8. Differences between the intestinal microbiota of rural African children and 
European children, as reported by De Filippo et al. (2010)
It is noteworthy to understand how the selection of the microbial populations during the 
evolution resulted in a clear functional distinctions, conferring an advantage to those bacterial 
groups that optimally degrade the available substrates. As demonstrated by Muegge et al. 
(2011), gene encoding for enzymes involved in amino acid metabolisms are differentiating 
carnivorous and herbivorous. Microbiomes from herbivores are enriched in enzymes that map 
to biosynthetic reaction for a number of amino acids, whilst enzymes involved in the amino 
acid degradation pathways are significantly enriched in carnivores. These results suggest that 
diet played a crucial role also in the evolution, allowing microbiomes of carnivorous to 
specialize in the proteins degradation as an energy source, whereas microbiomes of 
herbivorous have specialized to synthesize amino acid building blocks. Recently, Walter and 
Ley  (2011) reviewed the role of human evolution on changes to the intestinal microbiome. 
Notably, the invention of cooking has been described as a milestone for the evolutionary 
history of the microbiome and it represent a valuable paradigm in understanding how the gene 
content of the human microbiome have been shaped. Cooking induced the introduction of 
new toxins, i.e. the acrylamide produced by  Maillard reaction, and other xenobiotics which 
can be further transformed by gut bacterial genes, as the beta-glucuronidases which appear to 
be unique to the human gut ecosystem (Gloux et al., 2011; Walter and Ley, 2011). Supporting 
the hypothesis that different human populations with different diets reflect specific food 
adaptation on the genetic level of their gut microbes, it has been recently demonstrated that 
acquisition of novel genes by the resident microbiota is a suitable method of adaptation. 
Hehemann et al. (2010) reported the first experimental evidence that the consumption of non-
sterile foods containing environmental bacteria can lead to the acquisition of functional genes 
giving a metabolic advantage to the host. Bacteroides plebeius, a peculiar member of the 
microbiome from Japanese people, recently acquired the porphyrinase gene from the 
seaweed-associated marine bacterium Zobellia galactanivorans thanks to an event of lateral 
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gene transfer (LGT). The LGT of porphyrinase gene was a gut evolutionary response favored 
by the consumption of non-roasted dietary seaweed in Japanese sushi. Notably, this gene is 
undetected in North American microbiomes, and its presence in the microbiome allows 
Japanese to extract energy  from the red marine alga porphyrin through bacterial fermentation 
of this indigestible polysaccharide to SCFAs in the gut. 
That the intestinal microbial diversity  of the human gut was the result  of coevolution between 
microbial communities and their hosts was already proposed by Ley et al. (2006). In fact, it 
was suggested that the peculiar structure of microbial diversity  in the human gut  was the 
result of a natural selection operating at two levels: i) an host level, “top-down” selection on 
the community, favoring stable societies with a high degree of functional redundancy; ii) an 
opposing, “bottom-up” selection force, driving microbial cells to become functionally 
specialized (Fig. 9). 
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Figure  9. Schematic diagram of the selection 
processes operating in the human intestinal microbiota. 
Figure was reported by Ley et al. (2006); brown arrows 
indicate selection pressures, whereas black arrows 
indicate emergent properties acquired thanks to 
evolution.
Probiotics and human health
The Nobel Laureate Élie Metchnikoff is 
considered to be the inventor of probiotics. 
In 1907, Metchnikoff reported that “there 
are many useful microbes, amongst which 
the lactic bacilli”, recommending “to absorb 
large quantities of (these) microbes”. In 
particular, intrigued by the longevity  of the 
Caucasian population and its frequent 
consumpt ion o f f e rmen ted mi lk s , 
Metchnikoff proposed that the acid-
producing microorganisms in fermented 
dairy  products could prevent fouling in the 
large intestine and thus lead to a 
prolongation of the life span of the 
consumer (Metchnikoff, 1908). 
According to the Food and Agricultural 
Organization of the United Nations and the 
World Health Organization, probiotics are 
“Live microorganisms, which, when 
consumed in adequate amounts, confer a 
health benefit on the host” (FAO/WHO, 
2001). Notably, the definition does not 
mention the human origin of the bacterial 
strains as criteria for the selection and 
utilization of probiotics and, vice versa, it is 
based on the type of effect caused on the 
host. Accordingly, probiotics include 
exogenous and indigenous bacterial species 
that interact with various cel lular 
components within the intestinal ecosystem. 
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To be considered as probiotics, microorganisms should fulfill the following criteria: i) being 
non-pathogenic and non-toxic; ii) being able to survive through the GIT; iii) being stable 
during the intended product shelf life and contain an adequate number of viable cells to confer 
health benefit to the host. 
Nowadays, the consumer market for probiotic foods is > 1.4 billion euros with an estimated 
annual growth of ~7–8% in the 2008-2013 period (Saxelin, 2008) and in particular up to 20% 
of the fermented dairy  products contains probiotics (Wassenaar and Klein, 2008). Marketed 
probiotic formulations commonly contain specific lactic acid bacteria strains, mainly 
belonging to Bifidobacterium or Lactobacillus genera. Conversely, less frequently used are 
strains of Propionibacterium freudenreichii, bacilli or yeasts (Wassenaar and Klein, 2008). 
Many studies indicated probiotics as promising in the treatment of acute gastroenteritis, 
Clostridium difficile-associated and antibiotic-associated diarrhea or colitis, irritable bowel 
syndrome, allergy  and maintenance of remission in inflammatory bowel diseases (Floch et al., 
2011; Preidis and Versalovic, 2009). 
Probiotics have been demonstrated to exert health promoting effects through several proposed 
mechanisms (Fig. 10), which rely  on microbe-gut epithelium, microbe-immune system and 
microbe-microbe interactions. These mechanisms include: i) SCFAs production and 
enhancement of the barrier function of the intestinal epithelium; ii) suppression of growth and 
binding of pathogenic bacteria; iii) increased mucin production; iv) induction of antimicrobial 
and heat-shock protein production; v) alteration of the immune activity  of the host through 
modulation of host signaling pathways (Aragon et al., 2010; Ventura et al., 2009; Thomas and 
Versalovic, 2011). Furthermore, probiotics can alter colonic fermentation and stabilize the 
symbiotic microbiota (Spiller, 2008), improving the dynamic interplay  between the resident 
bacterial community and the host. 
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Since intestinal epithelial cells (IECs) are an initial point of contact between the host and 
intestinal microbes, adhesion to the intestinal epithelium is an important requisite for allowing 
probiotics to exert a beneficial role. Adhesion ability is strongly strain-dependent, therefore an 
evaluation of this characteristic is required as a selection criterium for novel probiotics 
(Collado et al., 2009). 
Even if a wide strain-specific variation in the immune response stimulated by probiotics has 
been described (Delcenserie et al., 2008), it can be generally regarded that probiotics can 
interact with the mucosa-associated immune system and bind to epithelial surface receptors, 
inducing humoral and cellular immune responses. The establishment and maintenance of a 
well-balanced ratio between pro- and anti-inflammatory cytokines are crucial for the human 
health. Cytokine secretion by IECs, macrophages and dendritic cells is regulated by probiotics 
through modulation of key signaling pathways such as NFκB and MAPKs. Changes in these 
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Figure  10. Overall scheme describing the mechanisms of actions of probiotics 
towards human intestinal cells (from Thomas and Versalovic, 2011).
pathways can also affect proliferation and survival of target cells. Through interactions with 
dendritic cells, probiotics can additionally influence T cell subpopulations and skew them 
towards a Th1, Th2 or Treg response (Thomas and Versalovic, 2011). 
Several in vitro and in vivo studies demonstrated two main effects of probiotics on the host 
immunity: i) strengthening the immunological barrier by stimulating the development and 
maintaining the state of alert of innate and adaptive immune system; ii) decreasing immune 
responsiveness to unbalanced inflammatory conditions. Both these health-promoting activities 
are accomplished through an effective modulation of the balance of pro- and anti-
inflammatory cytokines production (Vanderpool et al., 2008). Many probiotic species have 
been demonstrated to share a relatively common immune pattern, as a reduction in Th2 
cytokines (i.e., IL-4, IL-5, IL-6, IL-10, IL-13) or a shift towards Th1-mediated immunity (i.e., 
IL-2, TNF-α, IFN-γ production). 
Prebiotics and human health
At present, prebiotics represent a useful and established dietary  approach for influencing the 
composition of the human gut microbial community. The concept of prebiotics was 
introduced in 1995 by Gibson and Roberfroid as an alternative way  to modulate the gut 
microbiota. A more recent definition of the term is “a selectively  fermented ingredient that 
allows specific changes, both in the composition and/or activity  in the gastrointestinal 
microbiota that confers benefits upon host wellbeing and health (Gibson et al., 2004).
Generally, prebiotics are oligosaccharides or more complex saccharides that are selectively 
metabolized by some commensal groups, including species considered to be beneficial for the 
host. The concept of prebiotics has been recently formalized by the establishment of three 
scientific criteria that a food ingredient must satisfy  to be considered as prebiotic (Gibson et 
al., 2004): i) resistance to gastric acidity and hydrolysis by mammalian enzymes and 
26
gastrointestinal absorption; ii) substrate of fermentation by intestinal microorganisms 
belonging to the human microbiota; iii) selective stimulation of the growth and/or activity  of 
intestinal bacteria associated with health and wellbeing. 
Prebiotics are obtained either by extraction from natural sources, by  enzymatic hydrolysis of 
plant polysaccharides, and by trans-galactosylation reactions catalyzed by bacterial enzymes 
(Charalampopoulos and Rastall, 2011). Several complex oligosaccharides fulfill the three 
above mentioned criteria and can be effectively considered as prebiotics. Most promising 
prebiotics are non-digestible fructo-oligosaccharides (FOS), such as inulin and oligofructose. 
Inulins are common plant storage carbohydrates which are nutritionally classified as dietary 
fibers. Inulin-type fructans are present in a range of different plants including wheat, onion, 
banana, garlic, leek and Agave tequilana (Gomez et al., 2009). Transgalacto-oligosaccharides 
(GOS) are a mixture of oligosaccharides derived from the enzymatic transglycosylation of 
lactose, and are among the best characterized prebiotic ingredients (Torres et al., 2010). 
Besides FOS and GOS, several other potential prebiotic compounds have been identified, 
such as isomalto-oligosaccharides (IMO), lactosucrose, xylo-oligosaccharides (XOS), 
soyabean oligosaccharides and gluco-oligosaccharides. However, evidences are still not 
sufficient for the classification of these oligosaccharides as prebiotics in accordance with the 
three rules reported above. Recently, the prebiotic potential of oat bran (Kedia et al., 2009) 
and a new potential IMO-type prebiotic compound, panose (Mäkeläinen et al., 2009), have 
been also investigated.
Several dietary  fibers, including non-starch polysaccharides, whole-grain, cellulose, dextrans, 
chitins, pectins, β-glucans and waxes have been reported to potentially provide similar 
beneficial effects as those of inulin-type fructans (Laparra and Sanz, 2010; Costabile et al., 
2008; Napolitano et al., 2009). 
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The biological effect of prebiotics mainly depends on their influence on the gut microbiota 
composition and metabolism, exerted through a number of different functional properties 
(Fig. 11), such as increased host absorption of mineral calcium and magnesium, prevention of 
pathogen adhesion and colonization, modulation of bowel habits, regulation of lipid and 
glucose metabolism and influence of the intestinal metabolome (Candela et al., 2010; Saulnier 
et al., 2009; Sherman et al., 2009). 
For example, it has been reported that oligofructose supplementation lowers hunger, promotes 
weight loss and improves glucoregulation in obese and healthy  adults (Parnell and Reimer, 
2009). The mechanism by  which the prebiotics modulation of gut microbiota impacts on the 
appetite sensation is poorly understood, however it has been suggested that prebiotics could 
modulate the intestinal microbiota, lowering the high-fat diet-induced LPS endotoxaemia and 
systemic and liver inflammation (Cani et al., 2009). 
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Figure  11. Overall scheme describing the mechanisms of actions of prebiotics 
towards human intestinal cells (from Saulnier et al., 2009).
Very  recently, it  has been further demonstrated that prebiotic-enriched pasta could be a useful 
dietary tool to manipulate gut microbiome-mediated well-being endpoint (Russo et al., 2010; 
2011).
The influence of prebiotics on host immunity, defense and inflammatory processes represents 
another interesting biological aspect of these food ingredients. Indeed, prebiotics effects may 
influence the immune system both directly or indirectly, through different proposed 
mechanisms, which have been extensively  reviewed by Roberfroid et al. (2010): i) immune 
modulation of prebiotics can result  from the compositional modification of the intestinal 
microbiota upon their ingestion and fermentation. This can lead to increased or depleted 
concentrations of peculiar microbial genus or species, which may change the overall immuno-
interactive profile of the microbiota; ii) microbial products, mainly  SCFAs, may interact with 
immune cells and enterocytes and modify their activity. In fact, that SCFAs modulate cytokine 
expression in intestinal epithelial cells is a matter of fact, since it has been demonstrated that 
they  are able to differentially  affect pro-inflammatory IL-2 and IFN-γ and immunoregulatory 
IL-10 production. Furthermore, it has been recently proposed the importance of SCFAs 
ligation to GPR43 to maintain intestinal homeostasis; iii) the potential direct ligation of 
pattern recognition receptors on immune cells by prebiotic carbohydrate structures may result 
in immunomodulation.
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PROJECT OUTLINE
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CHAPTER 2 - PROJECT OUTLINE
The role of the human gut microbiota in impacting host’s health has been widely studied in 
the last decade. In particular, the development of “omics” techniques allowed researchers to 
integrate in a holistic view the complementary knowledge deriving from studies on the 
composition, functional activity and metabolism of the billions of microbial cells which are 
thriving in our intestine (Maccaferri et al., 2011).
Notably, it has been recently shown that diet and nutritional status are among the most 
important modifiable determinants of human health. Through the plethora of presumptive 
mechanisms, microbiota-mediated processes are thought  to have a relevant role (Kau et al., 
2011).
At present, probiotics and prebiotics represent a useful and established dietary approach for 
influencing the composition and activity of the human gut microbial community. Notably, the 
consumer market for probiotics, prebiotics and functional foods is > 1.4 billion euros, with an 
estimated annual growth of about 7-8% in the 2008-2013 period. (Saxelin, 2008). 
The present study is composed of two main sections aimed at elucidating the probiotic 
potential of the yeast strain K. marxianus B0399, as well as the putative prebiotic activity 
ascribable to four different flours, naturally enriched in dietary fibres content.
Firstly, several potential probiotic traits of K. marxianus B0399 were investigated by using in 
vitro assays, including adhesion and immune modulation. The effect of the administration of 
107 CFU/day of K. marxianus B0399 on the composition and metabolic activity of the human 
intestinal microbiota was investigated in a 3-stage continuous-culture system simulating the 
human colon. The promising results demonstrating that this lactic yeast strain possesses a 
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number of beneficial and strain-specific probiotic properties (Maccaferri et al., 2012), 
substantiated further in vivo studies. In particular, we investigated if the daily administration 
of a novel probiotic yoghurt containing B. animalis subsp. lactis Bb12 and K. marxianus 
B0399 could impact  on the biostructure of IBS microbiota, modulating its composition 
towards a healthy-like pattern. Indeed, this yoghurt  was demonstrated to have beneficial 
effects in the management of IBS symptoms (Lisotti et al., 2011).
Additionally, we investigated the impact of four flours (Wholegrain rye, wholegrain wheat, 
chickpeas and lentils 50:50, and barley milled grains), characterised by a naturally high 
content in dietary fibres, on the intestinal microbiota composition and metabolomic profiles. 
These studies combined molecular and cellular analysis, performed in order to evaluate 
composition the activity of the human colonic microbiota, with a NMR metabolomics 
approach for determining the impact of potential prebiotic fibres on the intestinal 
metabolome.
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KLUYVEROMYCES MARXIANUS B0399: 
IN VITRO AND IN VIVO  CHARACTERISATION OF 
A NOVEL PROBIOTIC YEAST ON THE HUMAN GUT ECOSYSTEM
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Increasing evidence is substantiating the 
utilisation of beneficial microbes in 
functional foods, dairy  products or other 
dietary supplements aimed at maintaining 
and promoting human health (Jankovic et 
a l . , 2 0 1 0 ) . P r o b i o t i c s h a v e b e e n 
demonstrated to exert health-promoting 
e f f e c t s t h r o u g h s e v e r a l p r o p o s e d 
mechanisms, including SCFAs production 
and enhancement of the barrier function of 
the intestinal epithelium, suppression of 
growth and binding of pathogenic bacteria, 
alteration of the immune activity  of the host 
(Aragon et al. , 2010; Thomas and 
Versalovic, 2011; Ventura et al., 2009). 
Adhesion to the intestinal epithelium is an 
important requisite for allowing probiotics 
to modulate the immune system. Since 
adhesion ability is strongly strain-
d e p e n d e n t , a n e v a l u a t i o n o f t h i s 
characteristic is required as a selection 
criterium for novel probiotics (Collado et 
al., 2009). Probiotics can interact with the 
mucosa-associated lymphoid tissues and 
bind to epithelial surface receptors, inducing 
humoral and cellular immune responses. 
The establishment and maintenance of a 
well-balanced ratio between pro- and anti-
inflammatory cytokines are crucial for the 
human health. Therefore, studying the 
dynamic cytokines modulation (Tab. 1) 
elicited by a microorganism represents a hot 
topic in the selection of novel probiotic 
strains. A wide strain-specific variation in 
the immune response stimulated by 
probiotics has been described, and several in 
vitro cell models have been developed to 
evaluate their immunomodulatory effects 
(Delcenserie et al., 2008). 
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Immune mediators Major functions
Tumour necrosis factors TNF-α, TNF-β Activation of immune cells, 
induction of apoptosis, pro-
inflammatory functions
Interleukins IL-1 α/β, IL-1ra, IL-2, IL-4, IL-5, 
IL-6, IL-7, IL-9, IL-10, IL-12, 
IL-13, IL-15, IL-17.
Regulation of immune cell 
function and activation
Transforming growth factors TGF-β Inhibition of cell growth, anti-
inflammatory, induction of IgA 
secretion
Interferons IFN-α/β/γ Antiviral activity, inhibition of 
tumour cell growth, activation of 
immune cells
Chemokines CCL2, -3, -4, -5, CXCL8, -10 Chemotaxis and activation of 
immune cells
Colony-stimulating factors GM-CSF, G-CSF, IL-3 Growth and differentiation of 
hematopoietic cells
Growth factors EGF, FGF, PDGF Growth and differentiation of 
cells
Even if these cellular models lack the immune system complexity, they  allow to elucidate 
mechanisms involved in bacterial sensing by human colonocytes and immune competent cells 
(Boivirant et al., 2007). Functional foods commonly contain specific lactic acid bacteria 
strains, mainly belonging to Bifidobacterium or Lactobacillus genera. Less frequently  used 
are strains of Propionibacterium freudenreichii, bacilli or yeasts (Wassenaar and Klein, 2008). 
Kluyveromyces marxianus is a lactic yeast isolated from different dairy products, mainly kefir 
(Bolla et al., 2011; Farnworth, 2005; Jianzhong et al., 2009). While the importance of this 
species in food development and fermentation is well documented, characterisation of its 
putative probiotic activities is very limited (Kumura et al., 2004; Romanin et  al., 2011). 
Table 1. Summary of the main immune mediators
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Kumura et al. (2004) evaluated a limited number of probiotic activities (adhesion to human 
enterocyte-like Caco-2 cells, resistance in acidic conditions and stimulation of IL-8 synthesis) 
in yeasts of dairy origin, testing 8 species belonging to Candida, Debaryomyces, 
Kluyveromyces, Yarrowia and Saccharomyces genera, isolated from commercial blue cheese 
and kefir. Romanin et al. (2010) attempted to to select lactic yeast from kefir able to down-
regulate intestinal epithelial innate response.
Since the interest of the food industry  in the selection of novel candidate probiotic strains, we 
evaluated for the first time the probiotic potential of K. marxianus B0399, a strain isolated 
from whey and curds of cow’s milk and deposited (deposit number MUCL 41579) at Belgian 
Coordinated Collection of Microrganism (BCCM). This strain is of particular interest  for 
several reasons: (i) it  is included in the EFSA list of Qualified Presumption of Safety (QPS) 
biological agents added to food and feed (EFSA Panel on Biological Hazards, 2010); (ii) it is 
included in different functional foods, currently marketed in several countries; (iii) it is 
capable of survival during gastric transit, maintaining its vitality and fermentation capacity 
(Mustacchi et al., 2010).
Here, K. marxianus B0399 was assessed for its ability  to adhere to the human enterocyte-like 
Caco-2 cells. Furthermore, the capacity  to modulate the production of 27 immune-mediators 
(cytokines, chemokines and growth factors) in Caco-2 cells and peripheral blood mononuclear 
cells (PBMCs) was evaluated. Finally, the effect of the daily administration of 107 CFU of K. 
marxianus B0399 on the faecal microbiota of 2 individuals affected by constipation-Irritable 
Bowel Syndrome (IBS) was investigated using a continuous culture system simulating the 
human colon (Box n. 4). Indeed, IBS patients are generally considered an appropriate study 
group to support  claims on gastrointestinal discomfort intended for general population (EFSA 
Panel on Dietetic Products, Nutrition and Allergies, 2011). The 3-stage continuous culture 
colonic model system used in this study (Fig. 12) provides a controlled environment that can 
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be maintained in a steady state and that simulates the complexity and diversity of the 
microbiota. Therefore, it  represents a useful tool for monitoring the ecology  and the metabolic 
activities of colonic microbiota in relation to different external perturbations (Bahrami et al., 
2011; Maccaferri et al., 2010; Macfarlane et al., 1998). 
37
Figure  12. Scheme of the three-stage continuous culture system simulating the 
human colon, used in this study. 
BOX N. 4 - IN VITRO MODEL TO STUDY THE GUT MICROBIOTA
Access to human materials other than faeces, such as gut content and tissues, is 
often restricted for practical and ethical reasons. At the same time, animal digestive 
physiologies differ from humans and only  very  recently  humanised mice, harbouring a 
human-like microbiota have been introduced. Therefore, the insurmountable problem 
of inaccessibility of the digestive tract in healthy  people stimulated scientists to use 
gut peculiar characteristics to develop and improve several in vitro models, involving 
the use of pure cultures, defined mixed cultures and faecal material. These models 
can range from simple batch fermentation system, to sophisticated pH controlled 
multistage continuous culture systems. In vitro models are tools of striking interest for 
the investigation of microbe-mediated processes that occur in the colonic lumen. 
Especially, multistage continuous cultures facilitate long-term studies and allow 
perturbations to the microbiota to be investigated under steady-state conditions. 
According to Longland (1991), an adequate gastrointestinal in vitro model should have 
the following characteristics: i) physiological quantities of enzymes should be used in 
sequence; ii) the pH should allow the activation of enzymes and other cofactors (i.e., 
bile salts and coenzymes); iii) digestive end products should be removed from the 
system; iv) at each stage, digesta should be adequately mixed; v) the transit rate 
should simulate the representative host species.
The simplest in vitro system to evaluate response of the gut microbiota to exogenous 
factors is the batch system. A batch system consists of a single, self-contained 
vessel. This method is rapid, inexpensive but does not allow addition or removal of 
nutrients from the vessel.
Gibson and colleagues (1988) developed a three-stage continuous culture system, 
designed to reproduce spatial, temporal, nutritional, and physicochemical 
characteristics of the microbiota in the proximal and distal colons. This in vitro colonic 
model was validated on the basis of chemical and microbiological measurements on 
intestinal contents obtained from human sudden death victims (MacFarlane et al., 
1998). This model does not take into account host factors such as intestinal 
secretions, gut immunological events, or the absorption of bacterial metabolites, 
however it provides a useful and relatively  inexpensive tool for modelling the ecology 
and metabolic activities of large intestine bacteria, under different environmental 
conditions.
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Frequent sampling at various locations of the model and the possibility  to vary several 
parameters that influence the fermentative processes in the colon (i.e. pH and food 
transit time), enable detailed mechanistic insight into, such as the fermentation of non-
digestible carbohydrates or administration of probiotics, prebiotics and other 
xenobiotics. This colon model consists of three vessels arranged in series, with 
respective operating volumes of 280, 300 and 320 mL. Vessels feed into each other 
sequentially, thus representing the proximal, transverse and distal regions of the 
human colon in terms of pH and nutrient availability. Furthermore, to reproduce the pH 
characteristics of the large gut, each vessel has a different pH, respectively  of 5.5, 
6.2, and 6.8. A mixture of polysaccharides and proteins is used as carbon and 
nitrogen sources, and each fermentor is magnetically  stirred and maintained at a 
temperature of 37°C and under anaerobic conditions, in order to be as much as 
possible near to physiological conditions.
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Culture conditions of K. marxianus 
B0399
K. marxianus B0399 was routinely grown 
aerobically at 37°C in MV2 broth (lactose, 
40 g/L; casein, 20 g/L; peptone, 7.5 g/L; 
yeast extract, 1.5 g/L). The ability of K. 
marxianus B0399 to survive in the colonic 
model conditions was assessed incubating 
7.0 log CFU/mL of actively growing culture 
in complex Colonic Model Growth Medium 
(CMGM) (Macfarlane et al., 1998), at  37 °C 
in anaerobic conditions for 24 h.
The resistance of the yeast strain in an 
envi ronment s imula t ing the upper 
gastrointestinal tract was further in vitro 
evaluated, as previously described by 
Maragkoudakis et al. (2006). Briefly, 
actively  growing culture was harvested 
(10,000 x g for 5 min, at 4 °C) and washed 
t w i c e i n P B S . R e s i s t a n c e t o t h e 
environmental condition of the stomach was 
assessed resuspending the cells pellet  (final 
concentration 6.0 – 7.0 log CFU/mL) in 0.1 
mol/L PBS adjusted by HCl to pH 2, 
containing pepsin (3 mg/mL, Sigma-
Aldrich), and evaluating the viable colony 
counts after 3 h of incubation at 37 °C. Bile 
salts tolerance was tested assessing colony 
viability after 3 h incubation in MV2 broth, 
supplemented by 0.3% (w/v) Oxgall 
(Sigma). 
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Eukaryotic cells culture conditions
The human enterocyte-like Caco-2 cells were grown in Dulbecco's modified Eagle Medium 
(DMEM) supplemented with 1.5 g/L glucose, 10% heat-inactivated fetal calf serum 
(Cambrex), 1% non-essential amino acids (Sigma), penicillin (50 IU/mL) and streptomycin 
(50 µg/mL), at 37 °C in an atmosphere of 5% CO2. The growth medium was changed to fresh 
medium without the addition of antibiotics for the last  24 h incubation prior to performing the 
immunoassay and the adhesion assays.
The human colon adenocarcinoma HT29 cells were grown in DMEM  supplemented with 10% 
(w/v) fetal bovine serum, penicillin (50 IU/mL) and streptomycin (50 µg/mL), at 37 °C in an 
atmosphere of 5% CO2. 
PBMCs were isolated from healthy volunteers by density  gradient centrifugation 
(Lymphoprep, Nycomed Pharma). Cells were re-suspended in Roswell Park Memorial 
Institute-1640 culture medium [RPMI-1640 (Life Technologies)] supplemented with 10% (w/
v) foetal bovine serum (Thermo Fisher Scientific Inc.) and 0.23 mM  sodium pyruvate solution 
(Sigma). PBMCs (106 cells/mL) were cultured at 37 °C in a humidified atmosphere, 
containing 5% CO2.
Adhesion of K. marxianus B0399 to Caco-2 cells detected by qPCR
Adhesion to Caco-2 cells of K. marxianus B0399 was evaluated by quantification of Caco-2-
bound microorganisms via qPCR, as reported by Candela and colleagues (2008). Stationary-
phase-grown cells of the yeast and bacteria strains were washed and re-suspended at the cell 
density  of approximately  8 Log CFU/ml in DMEM. Caco-2 cells were washed with DMEM 
and 1 mL of DMEM, containing the yeast/bacterial suspension, was added. After incubation 
for 1.5 h at 37 °C under humidified atmosphere, unattached yeast or bacteria were removed 
by washing the monolayers four times with sterile PBS. After detachment of Caco-2 cells 
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from the plastic surface by treatment (15 min at 37 °C) with 200 µL trypsine/EDTA (Cambrex 
Bio Science) per well, Caco-2 cells and adhesive yeast or bacteria were transferred into a 1.5 
mL-reaction tube. To quantify  microbial cells by qPCR, cell suspensions were boiled for 5 
min and, after mixing, an aliquot of 20 µL was transferred into an 0.2 mL-reaction tube and 
incubated for 10 min at room temperature with 3.8 µL of Trypsin Inhibitor solution (Type I-S 
from Soybean, 1 mg/mL in HìO). Strongly-adhesive enterotoxigenic Escherichia coli H10407 
and mildly-adhesive Leuconostoc mesenteroides C5 were used as reference bacterial strains. 
Quantification of the reference bacterial strains was performed with E. coli species-specific 
primer set ECO-1/ECO-2 (Wang et al., 1996) and LAB-specific PCR primer set Bact-0011f/
Lab-0677r (Heilig et al., 2002), whereas yeast-specific primer set  NL1/LS2 (Cocolin et al., 
2000) was used to quantify K. marxianus B0399. qPCR was performed in a LightCycler 
instrument (Roche) and SYBR Green I fluorophore was used to correlate the amount of PCR 
product with the fluorescence signal. Quantification of bacterial and yeast  DNA was carried 
out using standard curves made from known concentrations of genomic DNA from the 
reference bacterial strains and K. marxianus B0399. The experimental protocol consisted of 
the following programs: (i) starting pre-incubation at 95 °C for 10 min; (ii) amplification 
including 30 cycles of 4 steps each at the temperature transition time of 20 °C/s: denaturation 
at 95 °C for 15 s, annealing at  63 °C (Bact-0011f/Lab-0677r) or 60 °C (ECO-1/ECO-2 and 
NL1/LS2) for 25 s, extension at 72 °C for 30 s, and fluorescence acquisition at 85 °C 
(Bact-0011f/Lab-0677r and NL1/LS2) or 88 °C (ECO-1/ECO-2) for 5 s; (iii) melting curve 
analysis: heating at  20 °C/s to 95°C; cooling at 20 °C/s to 60 °C with 15 s hold, and then 
heating 0.2 °C/s until 99 °C. Chromosomal DNA of the strains used as standards was 
extracted by using DNeasy Tissue Kit (Qiagen) and serially diluted from 106 to 103 CFU/µL. 
The data reported represent mean values obtained in 3–5 independent experiments. Each 
experiment was performed in duplicate.
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Immunoassay
K. marxianus B0399 cells, corresponding to a concentration of 1 x 106 CFU/mL, were applied 
to confluent  Caco-2 cells or PBMCs and incubated at 37 °C for 24 h. Unstimulated cells were 
used as a negative control, whereas LPS (1 µg/mL, Sigma) was used to stimulate eukaryotic 
cells. After incubation, supernatants from Caco-2 and PBMCs cultures were collected, 
centrifuged at 400 x g for 15 min at 4 °C and used to determine levels of several immune-
mediators by  using a multiplexed bead immunoassay. Caco-2 and PBMCs cells were checked 
for viability by Trypan blue exclusion. 
The concentration of 27 immune-mediators (Table 2) was measured using the human 
ultrasensitive cytokine 27-plex antibody bead kit (Bio-Rad). The assays were performed in 
96-well filter plates, as previously  described (Vignali, 2000). The concentration of the 
samples was estimated from the standard curve using a fifth-order polynomial equation and 
expressed as pg/mL after adjusting for the dilution factor (Bio-Plex Manager software version 
5.0). Samples below the detection limit of the assay were recorded as zero, while samples 
above the upper limit of quantification of the standard curves were assigned the highest value 
of the curve. The intra-assay CV averaged 17%. Experiments were performed in triplicate. 
For each single determination, 50 beads were read and standard deviation was calculated.
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Immune mediators Chemical class
Interleukin-(IL): IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, 
IL-12(p70), IL-13, IL-15, IL-17.
Interferon-γ (IFN-γ), Tumor Necrosis Factor-α (TNFα)
Cytokines
Monocyte Chemotactic Protein-1 (MCP-1), Macrophage Inflammatory 
Protein-1α (MIP-1α), Macrophage Inflammatory Protein-1β (MIP-1β), 
Regulated upon Activation, Normal T-cell Expressed and Secreted 
(RANTES), Eotaxin, IL-8, Interferon-γ-induced Protein-10 (IP-10)
Chemokines
Platelet-derived Growth Factor-BB  (PDGF-BB), Fibroblast Growth 
Factor (FGF basic), granulocyte colony-stimulating factor (G-CSF), 
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), 
Vascular Endothelial Growth Factor (VEGF)
Growth factors
Table 2. List of the immune-mediators evaluated in the present study
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Three-stage continuous culture colonic model system
The three-stage continuous culture model of the human colon comprised of 3 glass fermenters 
of increasing working volume, simulating the proximal (V1, 280 mL), transverse (V2, 300 
mL) and distal colon (V3, 320 mL). The 3 fermenters connected in series were kept at  37°C, 
pH was stably maintained at 5.5 (V1), 6.2 (V2) and 6.8 (V3) and anaerobic conditions were 
ensured by  continuously sparging with O2-free N2.V1 was fed by means of a peristaltic pump 
with CMGM (Macfarlane et al., 1998).
Human faecal samples were collected on site, kept in an anaerobic cabinet (10% H2, 10% 
CO2, 80% N2) and used within a maximum of 15 min after collection. This experiment was 
carried out in duplicate using faecal samples from two different volunteers suffering from 
constipation IBS. None of the volunteers had received antibiotics or probiotics for at least 3 
months before sampling. A 1:5 (w/w) faecal dilution in anaerobic PBS [0.1 M PBS (pH 7.4)] 
was prepared and the samples were homogenised in a stomacher (Seward Ltd.) for 2 min. 
Each stage of the colonic model was inoculated with 100 mL faecal slurry. Total system 
transit time was set at 72 h, according to mean retention time of adults suffering from 
constipation IBS. Following inoculation, the colonic model was run as a batch culture for a 24 
h period in order to stabilise bacterial populations prior to the initiation of medium flow. After 
24 h (T0) the medium flow was initiated and the system was run for 8 full volume turnovers 
to allow for steady  state to be achieved (SS1). Taking into account the operating volume (900 
mL) and the retention time (72 h) of the colonic model system, 3-5 x 107 CFU of actively 
growing K. marxianus B0399 were added daily to V1. The yeast strain was added to the 
system as described for a further 8 volume turnovers upon which steady state 2 (SS2) was 
achieved. Each steady state was confirmed through sampling on three consecutive days for 
SCFAs and fluorescence in situ hybridization (FISH) analyses. Samples for FISH were 
immediately fixed in 4% paraformaldehyde as previously described (Martín-Peláez et al., 
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2008). Samples for HPLC and cytotoxicity analysis were centrifuged and supernatants were 
frozen immediately, whereas cell pellets were resuspend in PBS/glycerol (1:1) and stored at 
-20 °C prior to proceed with DNA extraction.
Evaluation of the colonic microbiota composition by FISH, PCR-DGGE and 
qPCR
Concentration of the main intestinal bacterial groups in samples from the colonic model 
system was evaluated by FISH, as previously  described by Martín-Peláez et al. (2008). The 
probes used are reported in Annex 1 and were commercially synthesised and 5’-labelled with 
the fluorescent Cy3 dye (Sigma). 
Dynamics of yeast population during the study was assessed by  PCR-DGGE and qPCR. 
Frozen samples recovered from the colonic model system were thawed and aliquots (250 µL) 
were processed for DNA extraction as previously described by Maccaferri et al. (2010). 
Approximately  250 nucleotides of the 5’-end region of the 26S rRNA gene was amplified by 
PCR using the yeast-universal primer set NL1 (or GC-clamped NL1 for PCR-DGGE) and 
LS2, according to Cocolin et al. (2000). The PCR-DGGE experimental protocol was slightly 
modified by performing annealing at 56 °C for 25 s and extension at 72 °C for 30 s, in order 
to prevent cross-amplification of bacterial DNA. Band identity  was confirmed by comparison 
of the position in the gel length with those of reference yeast DNA, as well as by  band 
excision, re-amplification and sequencing. qPCR was performed as previously  described, 
using standard curves made from known concentrations of the genomic DNA of K. marxianus 
B0399, in order to quantify modifications in concentration of yeasts along the  experiment.
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Determination of short-chain fatty acids concentration by HPLC
Samples from each vessel of the colonic model system were centrifuged at 13,000 x g for 10 
min to remove bacterial cells and any particulate material. SCFAs (acetate, propionate, 
butyrate) and lactic acid concentrations were determined by HPLC on an Aminex HPX-87H 
column (300 x 7.8 mm, Bio-Rad). Degassed 5 mM H2SO4 was used as eluent at a flow rate of 
0.6 mL/min and an operating temperature of 50 °C. Organic acids were detected by  UV at a 
wavelength of 220 nm. Sample quantification was carried out using calibration curves 
standard for lactate, acetate, propionate and butyrate at  concentrations of 12.5, 25, 50, 75 and 
150 mM. Internal standard of 20 mM 2-ethylbutyric acid was included in the samples and 
external standards. 
Modulation of HT29 cells growth by K. marxianus B0399
The influence of colonic model supernatants, recovered before and after administration of K. 
marxianus B0399, on the growth and survival of the human colon carcinoma cell line HT29 
was determined using the growth curve assay, as previously described by  Maccaferri et al. 
(2010). Results are expressed as EC50, which represents the effective concentration of colonic 
model supernatants resulting in a 50% reduction of cell number under the specified cell 
culture and treatment conditions compared to the growth of untreated cells. 
Statistical analysis
All data were analysed by one-way  ANOVA, using Tukey’s post-test analysis when the 
overall P value of the experiment was below the value of significance (P < 0.05). An 
additional paired t-test was applied in order to assess the significance of results of single pairs 
of data. Analyses were performed using GraphPad Prism 5.0 (GraphPad Software). 
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CHAPTER 3 - IN VITRO 
EVALUATION OF THE 
PROBIOTIC ACTIVITY OF K. 
MARXIANUS B0399
1. Brief introduction
2. Materials and Methods
3. Results
4. Discussion
Adhesion of K. marxianus B0399 to 
Caco-2 cells
Adhesion ability of K. marxianus B0399 to 
Caco-2 cells was evaluated by  qPCR (Fig. 
13). Notably, K. marxianus B0399 showed 
adhesion value of 4.13 x 103 cells/100 
Caco-2 cells, whereas reference bacterial 
strains L. mesenteroides C5 (mildly-
adhesive bacterial strain) and E. coli 
H10407 (strongly-adhesive bacterial strain) 
showed adhesion values of 7.61 x 102 and 
10.56 x 104 cells/100 Caco-2 cells, 
respectively. According to Candela et al. 
(2008), who defined strongly  adhesive 
strains as those with more than 40 cells 
adhered to one Caco-2 cell, K. marxianus 
B0399 can be classified as a strongly 
adhesive strain. 
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Figure 13. Adhesion of K. marxianus B0399 (Km 
B0399) to Caco-2 cells, as evaluated by qPCR. 
The strongly adhesive enterotoxigenic E. coli 
H10407 (EcH10407) and mildly adhesive L. 
mesenteroides C5 (Lm C5) were used as control.  
Measurements were performed in triplicate. 
Results are means (number of cells of the target 
strain bound to 100 Caco-2 cells) ± SEM.
Immunomodulatory activity of K. marxianus B0399 towards PBMCs and Caco-2 
cells
The ability of K. marxianus B0399 to modulate the secretion of 27 immune-mediators in 
PBMCs and Caco-2 cells was tested. Unstimulated cells were used as negative control, whilst 
LPS-stimulated cells were used as positive control. 
The incubation of PBMCs with K. marxianus B0399 provoked a marked increase in 
concentration of the pro-inflammatory cytokines IL-1β, IL-6, IFN-γ, MIP-1α and TNF-α and 
a moderate yet significant increase in concentration of anti-inflammatory  cytokine IL-1Ra. 
Conversely, when LPS was used to trigger an inflammatory response, co-incubation with K. 
marxianus B0399 elicited a significant decrease in the concentration of pro-inflammatory 
TNF-α, ΙL-6, and MIP-1α, whereas IL-1β was significantly  increased in concentration. No 
significant variations were detected for IFN-γ and IL-1Ra after the co-incubation (Fig. 14).
The incubation of Caco-2 cells with K. marxianus B0399 provoked a significant decrease of 
secretion of the pro-inflammatory chemokine IP-10. When K. marxianus B0399 was co-
incubated with LPS, it induced a significant decrease of secretion of the pro-inflammatory 
cytokines IP-10, IL-8, IL-12, and IFN-γ (Fig. 15). 
The production of the other immune modulators by PBMCs and Caco-2 cells was not 
significantly modulated by K. marxianus B0399 in all the tested conditions.
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Figure 14. Levels of immune-mediators secreted by PBMCs, after stimulation with 
LPS, K. marxianus B0399 (Km B0399) and co-stimulation with LPS and yeast 
strain (Km B0399 + LPS). Measurements were performed in triplicate. Results are 
means (pg of immune-mediators per ml of cultural supernatant) ± SEM. Bars not 
sharing a common letter are significantly different at a confidence level of P < 0.05.
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Figure 15. Levels of immune-mediators secreted by Caco-2 cells, after stimulation 
with LPS, K. marxianus B0399 (Km B0399) and co-stimulation with LPS and yeast 
strain (Km B0399 + LPS). Measurements were performed in triplicate. Results are 
means (pg of immune-mediators per ml of cultural supernatant) ± SEM. Bars not 
sharing a common letter are significantly different at a confidence level of P < 0.05.
Survival of K. marxianus B0399 in simulated gastrointestinal conditions
K. marxianus B0399 was confirmed to survive in gastric simulated conditions, since 
incubation for 3 h at pH 2 in presence of pepsin provoked a moderate decrease of yeast 
viability, from an initial concentration of 6.90 log CFU/mL to a final value of 4.97 log CFU/
mL. Similarly, survival was maintained when the strain was incubated for 3 h with 
physiological concentration of bile salts, with a slight decrease from 6.96 log CFU/mL to 6.63 
log CFU/mL. K. marxianus B0399 was further able to grow anaerobically in the colonic 
model system medium CMGM, reaching a final concentration of 8.38 log CFU/mL after 24 h 
(data not shown). 
Impact of K. marxianus B0399 on the colonic microbiota composition
Total yeasts population was evaluated in each vessel of the colonic model system before 
(SS1) and after (SS2) the daily administration of K. marxianus B0399 by  PCR-DGGE. PCR-
DGGE, whose sensitivity (~105 yeast cells/mL) was not sufficient to detect yeasts in the 
fermentation system before the intervention, confirmed the presence of a clear band 
corresponding to K. marxianus in V1 and V2 at SS2 (99% identity with K. marxianus 
13MCHS 26S ribosomal RNA gene, Annex 2). Furthermore, qPCR analysis confirmed that 
the total yeast population in V1, V2 and V3 at SS1 was below the detection limit of the 
method (2.5 x 102 CFU/mL), whilst  at SS2 yeasts reached the following concentrations: V1, 
3.7 ± 0.9 x 107 CFU/mL; V2, 6.1 ± 0.6 x 104 CFU/mL; V3, < 2.5 x 102 CFU/mL.
The concentration of the main bacterial groups constituting the core of the human intestinal 
microbiota was assessed before and after supplementation of K. marxianus B0399 by FISH 
(Fig. 16). 
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Figure 16. Bacterial groups detected by FISH in the culture broth recovered from 
each vessels (V1, V2 and V3) of the colonic model system before (SS1) and after 
(SS2) the daily administration of K. marxianus B0399. Results are reported as 
mean of the data of two colonic models (Log10 cells/mL) ± SEM. For each colonic 
model, measurements were performed in triplicate at SS1 and SS2. **P < 0.01; 
***P < 0.001.
Yeast administration did not mediate any significant modification in the total bacteria counts 
(EUB338 I-II-III) during the intervention. FISH analysis showed that Clostridium cluster 
XIVa (Erec482) and cluster IX (Prop853) were the predominant bacterial groups in the 
colonic microbiota, and that K. marxianus B0399 addition did not  significantly influence (P > 
0.05) their concentration. A similar behaviour was demonstrated for Bacteroides (Bac303), 
Faecalibacterium prausnitzii (Fprau655), the subdominant lactic acid bacteria (Lab158), 
Roseburia intestinalis-Eubacterium rectale group (Rrec584), Clostridium cluster I and II 
(Chis150), Atopobium cluster (Ato291) and δ-Proteobacteria (DELTA495 a-b-c), whose 
concentrations were stably maintained during the study. 
Notably, administration of K. marxianus B0399 provoked a significant increase in bacteria 
belonging to the health-promoting genus Bifidobacterium (Bif164) in the first and second 
stages of the colonic model system (7.57 to 7.96 log CFU/mL in V1, P = 0.0004; 7.78 to 8.12 
log CFU/mL in V2, P = 0.009). 
Impact on SCFAs production by K. marxianus B0399 
SCFAs (acetate, propionate and butyrate) and lactic acid were detected and quantified by 
HPLC in the three different stages of the colonic model systems, at SS1 and SS2. 
The administration of K. marxianus B0399 induced a significant increase of acetate (64.58 to 
76.02 mM, P = 0.02) and propionate (57.42 to 70.16 mM, P = 0.0005) over the course of the 
experiment. In particular, acetate increased significantly in the first stage of the colonic model 
system, whereas propionate increased significantly  in the first and second stages of the 
colonic model system (Fig. 17). Conversely, no significant modification in lactate and 
butyrate concentrations occurred. 
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Cytotoxic effects of colonic model supernatants
EC50 was used to compare the effect of colonic model supernatants, before and after the 
administration of K. marxianus B0399, on HT29 cell growth (Fig. 18). No significant changes 
between EC50(SS1) and EC50(SS2) were found in the second and third stages of the colonic 
model system. Conversely, V1 colonic model supernatants after the administration of the 
yeast strain were significantly less cytotoxic than at SS1 (EC50 SS1: 3.35 vs. SS2: 4.23, P < 
0.05). 
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Figure 17. Short-chain fatty acids concentrations in the culture broths recovered 
from each vessels (V1, V2 and V3) of the colonic model before (SS1) and after 
(SS2) the daily administration of K. marxianus B0399, as assessed by HPLC.
Results are reported as mean of the data of two colonic models (mM)  ± SEM. 
For each colonic model, measurements were performed in triplicate at SS1 and 
SS2. *P < 0.05; ***P < 0.001.
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Figure 18. Cytotoxic effect of supernatants recovered from Vessel 1 (A), Vessel 2 
(B), and Vessel 3 (C) of the colonic model system, before (SS1) and after (SS2) 
administration of K. marxianus B0399. 
Cytotoxicity was assessed by co-incubating HT29 cells with increasing 
concentration (0%, 1%, 2.5%, 5%, 10%) of fermentation supernatants (filled circle: 
SS1, filled square: SS2, star: Gut Model Medium) followed by DAPI staining. 
Results are expressed as means of relative HT29 cell growths (%) of 2 colonic 
models ± SEM. For each colonic model, measurements were performed in 
triplicate. EC50 values were calculated from the growth curves shown in Figures 
18A, B, and C for SS1 and SS2. Figure 18D shows the comparison of EC50 values 
in SS1 and SS2 for each vessel. *P < 0.05
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In recent years, an evolving number of 
studies suggested that the administration of 
probiotics plays a role in human health-
promotion. In the present study, we assessed 
the probiotic potential of the food-grade 
yeas t s t ra in K. marxianus B0399, 
investigating a number of traits such as: i) 
adhesion to the intestinal epithelium; ii) 
modulation of the immune response; iii) 
impact on the composition and fermentation 
potential of the human colonic microbiota; 
iv) modulation of the cytotoxicity of the 
microbiota metabolites.
Using Caco-2 cells, a largely  accepted in 
vitro model, we demonstrated that  K. 
marxianus B0399 is a strongly  adhesive 
strain. It is noteworthy that health-
promoting effects of probiotic strains might 
be partly dependent on their persistence in 
the intestine and adhesion to mucosal 
surfaces (Collado et al., 2009).
A further important characteristic of 
potential probiotic candidates is the capacity 
to modulate the immune response of the 
host. In fact, a finely tuned balance between 
immune responses and tolerance to the gut 
microbiota is required at the edge of the 
colonic epithelium for preventing intestinal 
inflammation. Several in vitro and in vivo 
studies demonstrated two main effects of 
probiotics on the host immunity: i) 
strengthening the immunological barrier by 
s t i m u l a t i n g t h e d e v e l o p m e n t a n d 
maintaining the state of alert of innate and 
adaptive immune system; ii) decreasing 
immune responsiveness to unbalanced 
inflammatory conditions. 
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Both these health-promoting activities are accomplished through an effective modulation of 
the balance of pro- and anti-inflammatory cytokines production (Vanderpool et al., 2008). 
Many probiotic species have been demonstrated to share a relatively common immune 
pattern, as a reduction in Th2 cytokines (i.e., IL-4, IL-5, IL-6, IL-10, IL-13) or a shift towards 
Th1-mediated immunity  (i.e., IL-2, TNF-α, IFN-γ production). However, distinctive effects 
are often strain-specific and therefore the assessment of the immune potential of novel 
probiotics is a challenging research area in food microbiology (Collado et al., 2007; 
Delcenserie et al., 2008). Nowadays, very  little is known about the immune potential of 
Kluyveromyces genus (Romanin et  al., 2010). In the only  study to date reported in literature, 
Romanin et al. (2010) demonstrated that probiotic Kluyveromyces spp. isolated from kefir 
counterbalanced the inflammatory action of flagellin, inducing a down-regulation of NF-
kappaB signalling in epithelial cells in vitro, as well as expression of other pro-inflammatory 
chemokines such as CXCL8 and CXCL2. 
In the present study, we evaluated the immunomodulatory  potential of K. marxianus B0399 
towards human PBMCs and Caco-2 cells. In PBMCs, K. marxianus B0399 induced the 
production of the pro-inflammatory  cytokines IL-1β, TNF-α, IFN-γ and IL-6, which are 
known to play  a crucial role in the host defence mechanism. A similar IL-6 and TNF-α 
overproduction was demonstrated in PBMCs exposed to well-established probiotic strains of 
lactobacilli, streptococci, Leuconostoc spp. and B. breve (Gaudana et al., 2010; Kekkonen et 
al., 2008; Timmerman et al., 2007). Notably, when K. marxianus B0399 was co-incubated 
with LPS, the concentration of TNF-α and IL-6 decreased to values similar to those detected 
in yeast-stimulated PBMCs without LPS. These data are in agreement with previous findings, 
which demonstrated that probiotic L. rhamnosus and L. gasseri strains were capable to 
diminish in different manner the release of TNF-α, IL-6 and IFN-γ in LPS-stimulated 
macrophage and PBMCs (Matsumoto et al., 2005; Pena et al., 2003). Interestingly, a similar 
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behaviour was also determined using the in vitro model system Caco-2 cells. In fact, in 
presence of a co-stimulation with K. marxianus B0399 and LPS, a significant decrease in 
concentration of the pro-inflammatory cytokines IFN-γ and IL-12 and chemokines IP-10 and 
IL-8 was demonstrated. In particular, a decreased production of IL-8 in response to 
inflammatory stimuli (LPS, TNF-α, IL-1β, enteropathogenic bacteria) was described for a 
wide array of probiotic bacteria (Candela et  al., 2008; Frick et al., 2007; Kamada et al., 2008). 
Indeed, a massive and protracted IL-8 release by colonocytes, associated with 
enteropathogenic infections, leads to a persistent inflammation and epithelial barrier 
dysfunction (Roselli et al., 2006).
The ability of K. marxianus spp. to modulate the composition and the functional activity of 
the human intestinal ecosystem is poorly  understood. In this perspective, we aimed at 
investigating how the K. marxianus B0399 administration impacts on the gut ecosystem, 
using a three-stage colonic model system that simulates the human colon.
Yeast administration did not mediate any significant modification in the total bacterial counts 
nor in the concentration of the predominant and subdominant bacterial groups. Notably, 
administration of K. marxianus B0399 provoked a significant increase in bacteria belonging 
to the health-promoting genus Bifidobacterium in the first and second stages of the colonic 
model system, which simulate the proximal and transverse colon. Whilst the metabolic 
potential of K. marxianus in the human gut has not been fully explored, it has been reported 
that this yeast can improve the growth and survival of bifidobacteria in complex food matrices 
(Rada, 1997). Indeed, it has been described that LAB growth can be stimulated by vitamins or 
amino acids produced by yeasts (Roostita and Fleet, 1996). Furthermore, it cannot be 
excluded that a small fraction of the K. marxianus B0399 added to the colonic model partially 
auto-lysates, releasing polysaccharides such as glucan and mannan, main constituents of the 
yeast cell wall. These polysaccharides can be converted into oligosaccharides, which are 
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known to stimulate the growth of Bifidobacterium spp. in the human and animal intestines 
(Belem and Lee, 1998)).
The administration of K. marxianus B0399 induced a significant increase of acetate and 
propionate over the course of the experiment. SCFAs, main end products of the carbohydrate 
fermentation, are demonstrated to play a pivotal role in the physiology and metabolism of the 
human colon. In particular, they provide energy for the intestinal colonocytes and promote 
epithelial cell growth (Jacobs et al., 2009). Even if the fermentation capability of K. 
marxianus to produce acetate has been described (Fonseca et al., 2007), the increase in 
concentration of acetate is consistent with the yeast-mediated modification in composition of 
the colonic microbiota, since Bifidobacterium spp. are principal producers of acetate (Jacobs 
et al., 2009). The relevant increase of acetate concentration in the colonic model system 
represents a valuable endpoint of the probiotic supplementation, since decreased levels of 
acetate and propionate have been correlated with gut metabolic profiles of patients affected by 
a variety of functional gastrointestinal disorders (Huda-Faujan et al., 2010; Marchesi et al., 
2007). 
Finally, we demonstrated that the administration of K. marxianus B0399 modulated a 
decrease of the cytotoxic potential of the cultural supernatant from the first vessel of the 
colonic model system. Our results are in agreement with those reported in literature, which 
showed that alteration of gut microbiota related to probiotic consumption may alter various 
parameters of faecal water activity  by reducing toxicity (Pearson et al., 2009). The aqueous 
phase of human faeces contains bioactive compounds likely to interact with colonic 
epithelium. They include potentially  harmful components, such as bile acids, fatty  acids, N-
nitroso compounds and heterocyclic amines, as well as compounds that are potentially 
beneficial, such as polyphenols and SCFAs (Pearson et  al., 2009). Indeed, cytotoxicity of 
faecal water is reported to be a risk biomarker, since several studies correlated toxicity of this 
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faecal fraction with a higher colonic cell proliferation and increased colon cancer risk 
(Glinghammar et al., 1997). 
In conclusion, the effects of K. marxianus B0399 on adhesion, immune function and colonic 
microbiota demonstrate that this strain possesses a number of beneficial and strain-specific 
properties desirable in a microorganism considered for application as a probiotics. 
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In physiological conditions, despite 
conservation at the highest taxonomic ranks, 
the intestinal microbiota is markedly 
individual-specific at species level, and a 
host-driven “top-down” assembly of the 
symbiotic microbial community has been 
suggested (Benson et al., 2010). Recently, it 
has been hypothesised that high taxonomic 
level unbalances of the human gut 
microbiota can be responsible for important 
modifications of the host physiological 
status, being associated with a number of 
gastrointestinal disorders (Mazmanian et al., 
2008; Turnbaugh et al., 2009; Maccaferri et 
al., 2011). Irritable Bowel Syndrome (IBS) 
is the prevalent functional GIT disorder with 
a worldwide prevalence of 10-20% 
(Longstreth et al., 2006). IBS sufferers can 
be grouped into three main symptom 
subtypes: diarrhoea-predominant IBS (D-
IBS), constipation-predominant IBS (C-
IBS) and mixed bowel habit IBS (M-IBS). 
The cause of the disease is thought to be 
multifactorial and may include dysmotility, 
abnormal gut sensation, genetic, microbial 
and dietary factors, as well as low-grade 
inflammation (Codling et al., 2009). Several 
studies using qPCR, FISH and sequencing 
of 16S rDNA libraries reported an intestinal 
dysbiosis in patients suffering from IBS, in 
terms of specific compositional changes 
associated with the disorder (Malinen et al., 
2005; Kassinen et al. 2007; Kerckhoffs et 
al., 2009; Tana et al., 2010; Maukonen et al., 
2006; Lyra et al., 2009). However, in most 
of these studies, the overall microbiota was 
not covered, as the quantified bacteria were 
predetermined according to primer or probe 
sequences. 
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Only very recently, Rajilić-Stojanović  et al. (2011) performed an in depth analysis of the 
human intestinal microbiota in IBS using a phylogenetic microarray  targeting the bacterial 
16S rRNA gene, demonstrating a significant decrease of Bacteroidetes (mainly belonging to 
Bacteroides and Prevotella), bifidobacteria and Faecalibacterium prausnitzii, and an increase 
in Firmicutes.
In the present  study, we aimed at characterising the intestinal microbiota of 19 subjects 
suffering from diagnosed IBS (10 D-IBS, 5 M-IBS, 4 C-IBS), who were enrolled in a 
monocentric trial for evaluating the efficacy  of a novel probiotic yoghurt (Lisotti et al., 2011) 
Indeed, different studies have suggested how probiotics may alleviate IBS symptoms and 
several mechanisms of action have been proposed (Marteau, 2010; Spiller, 2008).  The novel 
dairy  probiotic preparation investigated in the present study contained Lactobacillus 
delbrueckii subsp. bulgaricus and Streptococcus thermophilus and was supplemented with B. 
animalis subsp. lactis Bb12, which has been described as part  of a probiotic formulation 
useful to manage IBS (Simrén et al., 2010; Søndergaard et  al., 2011) and K. marxianus 
B0399, a novel probiotic lactic yeast we have been recently  characterising for its potentially 
beneficial properties (Maccaferri et al., 2012).
A fully  validated High Taxonomic Fingerprint Microbiota Array (HTF-Microbi.Array; 
Candela et al., 2010) was used to characterise the intestinal microbiota of the IBS subjects. 
This DNA microarray, based on the LDR technology  (Castiglioni et al., 2004), is a highly 
specific, reproducible and sensitive tool that enables specific detection and approximated 
relative quantification of 16S rRNAs from 30 phylogenetically related groups, which cover 
about the 95% of the human intestinal microbiota (Rajilić-Stojanović et al., 2007). Differently 
from other DNA microarray platforms already reported in literature, the HTF-Microbi.Array 
is specifically  designed to monitor the high level taxonomic unbalances of the core functional 
microbiome that could have an impact on the host physiological status (Mazmanian et  al., 
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2008; Turnbaugh et al., 2008; Hamady and Knight, 2009). Conversely, it  remains blind to the 
species-level inter-individual variability. In the perspective of assessing the most relevant 
unbalances characterising the IBS microbiota, we compared compositional data from the 
faecal microbiota of IBS subjects obtained before the probiotic intake against  a cohort of 24 
healthy adults, comparable for sex and age, deriving from previous descriptive studies 
(Candela et al., 2010; Candela et al., 2011, personal communication). Finally, since the dairy 
probiotic product tested in this study has been demonstrated to improve bloating, bowel 
movement abnormality, as well as reduce abdominal pain in IBS patients (Lisotti et al., 2011), 
we assessed if the IBS-associated unbalances of the intestinal microbiota were reverted by the 
probiotic yoghurt. 
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Subjects and study design
The study group consisted of 19 subjects 
suffering from diagnosed IBS, who were 
enrolled in the intervention study. IBS 
patients (mean age = 33.6 ± 9.1) fulfilled the 
Rome III criteria for the diagnosis of IBS 
(Longstreth et al., 2006).  Exclusion criteria 
included pregnancy or lactation, chronic 
intestinal disease (i.e., inflammatory bowel 
disease or coeliac disease) or severe 
systemic disorders, lactose intolerance or 
food allergies. Patients who in the 2 months 
prior to study entry had taken medication, 
such as antibiotics, corticosteroids or 
functional foods containing pre- or 
probiotics, were also excluded from the 
study. Each subject  signed the informed 
consent prior to enter the study. The study 
protocol was conforming to the ethical 
guidel ines of the “World Medical 
Association Declaration of Helsinki”. 
IBS patients were subjected to a 4-week 
study period, and were daily  receiving a 
probiotic yoghurt containing L. delbrueckii 
subsp. bulgaricus and S. thermophilus and 
supplemented with K. marxianus B0399 and 
B. animalis subsp. lactis Bb12. The total 
daily amount of K. marxianus B0399 was 
1-4 x 107 CFU, whilst the amount of B. 
animalis subsp. lactis Bb12 was 3-5 x 109 
CFU. Consumption of other probiotics was 
not allowed during the intervention. All 
subjects were advised to follow their usual 
dietary habits and not to undertake any 
medication. 
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For the comparative analysis of the IBS microbiota composition before the probiotic 
intervention, a cohort of 24 healthy subjects comparable for age and sex and already 
characterised for their intestinal microbiota profiling was considered. 
These compositional data were retrieved using the same analytical approach undertaken in 
this study (Candela et al., 2010; Candela et al., 2011, personal communication).
Faecal samples
During the study, two faecal samples were collected from each subject suffering from IBS. 
Samples were taken before beginning the probiotic supplementation for assessing the 
individual baseline, and after the 4-week supplementation. Samples were immediately stored 
in anaerobic containers and frozen within 4 h to -70°C until analysis.  
Extraction and purification of microbial DNA from faecal samples
Total microbial DNA was extracted using QIAamp DNA Stool Mini Kit (Qiagen) with a 
modified protocol, as previously  described by Biagi et al (2010). Final DNA concentration 
was determined by using NanoDrop ND-1000 (NanoDrop Technologies).
Characterisation of the intestinal microbiota by HTF-Microbi.Array
The intestinal microbiota of the IBS subjects enrolled in the study was characterised using the 
fully  validated DNA microarray HTF-Microbi.Array, which target 30 phylogenetically related 
groups. The analysis was performed at the baseline and after the 4-week probiotic 
supplementation. 16S rRNA was amplified using universal forward primer 16S27F and 
reverse primer r1492, following the protocol previously described (Candela et al., 2010). PCR 
products were purified by using a Wizard SV gel and PCR clean-up System purification kit 
(Promega Italia), according to the manufacturer's instructions, eluted in 20 µl of sterile water, 
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and quantified with the DNA 7500 LabChip Assay kit and BioAnalyzer 2100 (Agilent 
Technologies). 
Ligase Detection Reaction and hybridisation of the products on the universal arrays were 
performed according to the protocol described by Castiglioni et al. (2004). except for the 
probe annealing temperature, set at 60 °C.
PCR-DGGE analysis of the faecal samples
Studies on the microbial DNA fingerprints derived from PCR-DGGE analysis were 
performed for the IBS subjects, at  the baseline and following the 4-week probiotic 
supplementation. Amplification of the V2-V3 region of the bacterial 16S rRNA gene was 
carried out using the universal eubacterial primers GCclamp-HDA1 and HDA2, according to 
the protocol previously described by Maccaferri et  al. (2012). DGGE gel images were 
analysed using the FPQuest Software Version 4.5 (Bio-Rad). In order to compensate for gel-
to-gel differences and external distortion to electrophoresis, the DGGE patterns were aligned 
and normalized using an external reference ladder composed by  known bacterial species. 
After normalization, bands were defined for each sample using the appropriate densitometric 
curves. Bands constituting less than 1% of the total band area were omitted from further 
analysis. Similarity between DGGE profiles was determined by calculating the Pearson 
correlation. Clustering of the sample profiles was done using the UPGMA algorithm. 
Additionally, a Shannon diversity index was calculated to investigate the structural diversity 
of the microbial community.
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Culture-independent and -dependent detection of K. marxianus B0399 in the 
faecal microbiota
Dynamics of yeast population and detection of the administered yeast during the study were 
assessed by  PCR-DGGE and selective plate counting, respectively. Approximately 250 
nucleotides of the 5’-end region of the 26S rRNA gene were amplified by PCR using the 
yeast-universal primer set GC-clamped NL1 and LS2, according to Cocolin et al. (2000). The 
PCR-DGGE experimental protocol was slightly modified by performing annealing at 56 °C 
for 25 s and extension at 72 °C for 30 s, in order to prevent cross-amplification of bacterial 
DNA. Band identity  was confirmed by comparison of the positions in the gel length with 
those of reference yeast DNA.
Detection of the survival and quantification of the growth of K. marxianus B0399 along the 
intervention were performed by plate counting at 37°C in lactic-yeast selective MV2 agar. 1:5 
(w/w) faecal dilutions in anaerobic PBS [0.1 M PBS (pH 7.4)] were prepared and the samples 
were homogenised in a stomacher (Seward Ltd.) for 2 min. After homogenisation, faecal 
samples were serially diluted using 10-fold serial dilutions down to a final dilution of 10-5. All 
plating counts were performed in triplicate.
Statistics
All arrays were scanned with ScanArray 5000 scanner (Perkin Elmer Life Sciences), at 10 µm 
resolution. Fluorescent images were obtained with different acquisition parameters for both 
laser power and photo-multiplier gain, in order to avoid saturation. Fluorescence intensities 
were quantitated by ScanArray  Express 3.0 software, using the "Adaptive circle" option, 
letting diameters vary from 60 to 300 µm. To assess whether a probe pair was significantly 
above the background (i.e. was present or not), one-sided t-test was performed. 
Nonparametric Kruskal-Wallis test was used to determine the statistical differences among the 
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IBS subtypes and/or treatment conditions. Mann-Whitney U-test was used for pairwise 
comparisons. A P < 0.05 was considered statistically significant. Hierarchical clustering of 
HTF-Microbi.Array profiles was carried out using the statistical software R (http://www.r-
project.org). The Euclidean distance among sample profiles was calculated and Ward's 
method was used for agglomeration. Redundancy analysis and RDA ordination diagram were 
performed using CANOCO for Windows 4.02 and CanoDraw 3.10 (Microcomputer Power), 
respectively. Monte Carlo permutation test was done at 199 random permutations, in order to 
assess significant differences. 
Bacterial counts and DGGE parameters were analysed by one-way ANOVA, using Tukey’s 
post-test analysis when the overall P value of the experiment was below the value of 
significance (P < 0.05). An additional paired t-test was applied in order to assess the 
significance of the results of single pairs of data. Analyses were performed using GraphPad 
Prism 5.0 (GraphPad Software). 
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Characterisation of the intestinal 
microbiota in IBS subjects
High taxonomic fingerprints of the faecal 
microbiota of the IBS subjects were 
depicted by HTF-Microbi.Array  (Annex 3), 
and compared with those of healthy subjects 
deriving from previous descriptive studies 
(Candela et al., 2010; Candela et  al., 2011, 
personal communication). 
The main bacterial groups of the IBS 
microbiota were Clostridium cluster IV and 
XIV (25% and 21% of the total microbiota, 
respectively), followed by Bacteroides/
Prevotella (9.1%). Other subdominant 
bacterial groups found at relevant 
concentration in the IBS microbiota were 
lactic acid bacteria (7.8%, summing the hits 
of Lactobacillaceae family and those of the 
Lactobacillus species targeted by  the HTF-
Microbi.Array), as well as Veillonella genus 
( 5 . 7 % ) , B a c i l l i c l a s s ( 2 . 9 % ) an d 
Bifidobacteriaceae family (1.2%). 
Multivariate redundancy analysis of the 
relative abundance of targeted bacterial 
groups/species highlighted that the 
microbiota of IBS subjects is significantly 
different from that of healthy individuals (P 
< 0.05). Triplot of the RDA of the 
composition of the faecal microbiota of 
healthy and IBS subjects demonstrated that 
samples clearly  separated on the basis of the 
health status (Figure 19). Furthermore, a 
clear separation of M-IBS and C-IBS, with 
respect to D-IBS was demonstrated. 
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Figure 19. Triplot of the RDA of the microbiota composition of subjects suffering 
from IBS and healthy individuals. Healthy subjects (HS), M-IBS patients (M), C-IBS 
patients (C) and D-IBS patients (D) are indicated by yellow rectangles, green 
diamonds, black circles and purple square, respectively. Constrained explanatory 
variables (HS, M, C, D) are indicated by filled red triangles. Black arrows indicate 
responding bacterial subgroups that explain more than 15% of the variability of the 
samples. First and second ordination axes are plotted, showing 12.3% and 5.4% of 
the total variability in the dataset, respectively. 
Table 3, 4 and Figure 20 (A, B, and C) show the bacterial groups significantly (P < 0.05) 
altered in IBS subjects with respect to healthy  controls. In particular, the faecal microbiota of 
IBS subjects was demonstrated to be enriched in bacilli, Bifidobacteriaceae, Clostridium 
cluster IX, E. rectale and Lactobacillaceae. Notably, members of Enterobacteriaceae, E. 
faecium, C. difficile and Campylobacter spp. were also demonstrated to be enriched in the 
IBS microbiota, with respect to the faecal microbiota of healthy subjects. Conversely, the IBS 
microbiota was depleted in concentration of Bacteroides/Prevotella group and Veillonella 
genus. 
A number of significant variations in specific phylogenetic groups have been demonstrated 
not only  between IBS and healthy controls, but also among the different IBS subtypes or 
among each IBS subtype and healthy individuals (Table 3 and 4). Interestingly, C-IBS was 
different from D-IBS, with a significant depletion in E. rectale concentration (P = 0.024). On 
the other hand, M-IBS was different from D-IBS for a significant increase in L. buchnerii (P = 
0.045). 
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% of the total targeted microbiota
Target phylogenetic group IBS C-IBS D-IBS M-IBS HS
Bacillus cereus 1.04 0.9 1.04 1.17 0.29
Bacillus clausii 1.88 2.03 1.89 1.74 0.21
Bacteroides/Prevotella group 9.11 7.38 9.39 9.91 19.79
Bifidobacteriaceae 1.17 1.08 1.23 1.11 0.42
Bifidobacterium adolescentis 0.88 0.68 1.05 0.69 0.5
Bifidobacterium bifidum 0.68 0.62 0.72 0.67 0.47
Bifidobacterium breve 0.7 0.68 0.7 0.72 0.38
Bifidobacterium longum 0.8 0.79 0.83 0.76 0.41
Campylobacter spp. 0.64 0.65 0.61 0.7 0.41
Clostridium difficile 0.64 0.63 0.65 0.6 0.34
Clostridium cluster IX 1.1 1.14 1.16 0.96 0.54
Enterobacteriaceae 1.07 0.72 1.34 0.82 0.4
Enterococcus faecium 0.87 0.67 0.94 0.9 0.47
Eubacterium rectale 6.51 3.81 7.13 7.43 3.71
Lactobacillaceae 2.49 3.05 2.46 2.1 0.82
Lactobacillus casei 2.09 2.77 2.02 1.69 3.78
Lactobacillus salivarius 0.71 0.66 0.77 0.64 0.29
Lactobacillus buchnerii 1.56 1.37 1.1 2.62 0.69
Veillonella spp. 5.66 5.83 5.85 5.13 13.12
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Table 3. Bacterial groups significantly altered in IBS subjects (IBS; Constipation 
IBS, C-IBS; Diarrhoea IBS, D-IBS; Mixed IBS, M-IBS), with respect to healthy 
subjects (HS). Data are expressed as % of the total microbiota targeted by HTF-
Microbi.Array.
P value of comparison among the different study groups
Target phylogenetic group
IBS 
vs. 
HS
C-IBS 
vs.
D-IBS
C-IBS 
vs.   
M-IBS
D-IBS 
vs.   
M-IBS
C-IBS 
vs. 
HS
D-IBS 
vs. 
HS
M-IBS 
vs. 
HS
Bacillus cereus 4.00E-08 0.54 0.73 0.95 0.013 8.50E-09 0.016
Bacillus clausii 5.20E-09 0.95 0.9 0.59 3.90E-04 1.60E-05 5.90E-05
Bacteroides/Prevotella group 1.20E-05 0.64 0.56 0.77 0.0021 0.001 0.016
Bifidobacteriaceae 2.30E-08 0.95 0.73 1 0.0015 2.10E-05 2.40E-04
Bifidobacterium adolescentis 0.0013 0.45 0.73 0.44 0.25 0.0016 0.12
Bifidobacterium bifidum 0.0039 0.73 0.56 0.77 0.3 0.0055 0.14
Bifidobacterium breve 5.40E-04 0.95 0.9 0.59 0.17 0.0012 0.074
Bifidobacterium longum 3.80E-05 0.95 1 0.77 0.094 8.70E-05 0.039
Campylobacter spp. 9.30E-04 0.95 0.9 0.44 0.11 0.037 0.0021
Clostridium difficile 3.10E-04 1 0.9 0.86 0.13 0.001 0.051
Clostridium cluster IX 5.30E-06 0.73 0.73 0.95 3.90E-03 0.0012 0.0027
Enterobacteriaceae 2.00E-06 0.95 0.73 0.77 0.062 7.20E-05 9.50E-04
Enterococcus faecium 1.30E-06 0.3 0.19 0.95 0.21 8.00E-06 3.50E-04
Eubacterium rectale 1.70E-05 0.024 0.19 0.77 0.13 8.70E-05 0.0079
Lactobacillaceae 1.70E-05 0.64 0.9 0.59 0.024 0.001 0.0043
Lactobacillus casei 0.0046 0.45 0.29 0.86 0.53 0.013 0.03
Lactobacillus salivarius 5.30E-05 0.84 0.73 0.95 0.062 4.90E-04 0.022
Lactobacillus buchnerii 2.80E-04 0.64 0.19 0.045 0.21 0.013 1.60E-04
Veillonella spp. 0.0011 0.95 0.9 0.95 0.13 9.50E-03 0.03
74
Table 4. P values of the modifications among bacterial groups significantly altered 
in IBS subjects (IBS; Constipation IBS, C-IBS; Diarrhoea IBS, D-IBS; Mixed IBS, M-
IBS), with respect to healthy subjects (HS). Significance variations (P < 0.05) are 
visualized in bold.
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Figure 20 (A). Box plots of the HTF-Microbi.Array relative abundance percentages 
corresponding to probes which showed an overall significantly different response 
between IBS, C-IBS (C), D-IBS (D), M-IBS (M) and healthy subjects (HS). (P < 
0.05)
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Figure 20 (B). Box plots of the HTF-Microbi.Array relative abundance percentages 
corresponding to probes which showed an overall significantly different response 
between IBS, C-IBS (C), D-IBS (D), M-IBS (M) and healthy subjects (HS). (P < 
0.05)
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Figure 20 (C). Box plots of the HTF-Microbi.Array relative abundance percentages 
corresponding to probes which showed an overall significantly different response 
between IBS, C-IBS (C), D-IBS (D), M-IBS (M) and healthy subjects (HS). (P < 
0.05)
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Furthermore, the comparison of the IBS microbiota composition before and after intake of the 
probiotic yoghurt supplemented with B. animalis subsp. lactis Bb12 and K. marxianus B0399 
was performed. The microarray  datasets of the faecal microbiota of the IBS subjects analysed 
in the present study were hierarchically clustered on the basis of the signal intensity  of the 
HTF-Microbi.Array oligonucleotide probes (Figure 21). According to the main phylogenetic 
features of the faecal microbiota, two groupings were assessed. A marked inter-individual 
diversity was demonstrated, since the majority  of the samples before and after intervention 
clustered together, and no grouping according to the probiotic intervention was depicted.
Moreover, PCR-DGGE analysis was used to retrieve an additional picture on the dynamics of 
the bacterial community  before and after intervention. PCR-DGGE confirmed that the 
biodiversity of the intestinal microbiota was not influenced by the probiotic treatment, as 
assessed by the richness and Shannon indices (P  >  0.05). Mean values of the richness index 
ranged from 17.5 (T0) to 19.6 (T1), whereas mean values of the Shannon index ranged from 
2.75 (T0) to 3.02 (T1). Finally, the peak heights of DGGE densitometric curves were analysed 
using the Mann-Whitney  U-test, in order to assess if the most relevant single-species 
abundances were affected by the probiotic administration. No significant changes in species 
abundance were found when comparing T0 and T1. 
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Figure 21. Hierarchical clustering of the HTF-Microbi.Array profiles of IBS subjects 
before and after the probiotic administration. Microarray fingerprints at the baseline 
are indicated by t0, whereas fingerprints after the probiotic intervention are 
indicated by t1. Colour intensity represents the relative bacterial abundance in the 
sample, in relation to the study population. Euclidean distance and Ward's 
clustering method were applied to log-transformed data.
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Evaluation of the survival of K. marxianus B0399 along the probiotic 
intervention
The survival of K. marxianus B0399 along the probiotic intervention was tested using 
selective plate counting for lactic yeasts and semi-quantitative PCR-DGGE analysis followed 
by band identification. 
Total count  of faecal lactic yeasts showed negligible levels (< 100 CFU/g of faeces) at T0 in 
15/19 subjects (75%), whilst the remaining 4 subjects had a basal concentration of (3.2 ± 0.6) 
x 103 CFU/g. Following the probiotic treatment, 16/19 subjects (84% of the study  population, 
P < 0.001) were positive for yeast colonisation, which reached a T1 concentration of (4.3 ± 
1.2) x 105 CFU/g. The presence of K. marxianus within the micro-eukaryotic faecal 
microbiota was confirmed by  PCR-DGGE. PCR-DGGE analysis, whose sensitivity (~105 
yeast cell/mL) was not sufficient to detect K. marxianus at  T0, confirmed the presence of a 
clear band corresponding to K. marxianus (99% sequence identity with K. marxianus 
13MCHS 26S ribosomal RNA gene, Annex 2) at T1 in 14/19 subject (74% of the study 
population, P < 0.001). 
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Recently, a number of studies investigated 
the unbalances that characterise the 
intestinal microbiota of patients suffering 
from IBS (Codling et al., 2009: Malinen et 
al., 2005; Kassinen et al. 2007; Kerckhoffs 
et al., 2009; Tana et al., 2010; Maukonen et 
al., 2006; Lyra et al., 2009). However, the 
rationale beyond differences in the 
microbiota composition between IBS 
patients and healthy individuals is still 
evolving. Furthermore, a growing number of 
studies have evaluated the response of IBS 
to probiotics, and few recent systematic 
reviews and meta-analyses suggested that 
probiotics appear to be, to varying extent, 
effective or at  least  promising in the 
amelioration of the well-being status of IBS 
subjects (Marteau, 2010; Spiller, 2008; 
Ringel and Ringel-Kulka, 2011).
In the present study, we analysed the faecal 
samples of 19 subjects suffering from IBS 
enrolled in a clinical trial for the evaluation 
of the efficacy of a new probiotic yoghurt 
containing K. marxianus B0399 and B. 
animalis subsp. lactis Bb12 (Lisotti et al., 
2011). Firstly, we evaluated the shift in the 
microbiota composition of the IBS patients 
before the probiotic administration, by 
comparing their microbiota profiles with 
those of a cohort of 24 healthy subjects, 
matched for sex and age, and previously 
characterised (Candela et al., 2010; Candela 
et  al., 2011, personal communication). 
Successively, we assessed the impact of the 
probiotic yoghurt on the gut microbiota 
composition. 
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We demonstrated that IBS microbiota is different from that of healthy  individuals due to an 
unbalance in a number of commensal species, with an increase in relative abundance of 
lactobacilli, B. cereus and B. clausii, bifidobacteria, Clostridium cluster IX and E. rectale, and 
a decrease in abundance of Bacteroides/Prevotella group and Veillonella genus. Furthermore, 
we demonstrated that some bacterial groups of the human intestinal microbiota, recently 
defined as pathobionts, are increased in concentration in the IBS microbiota. The so-called 
pathobionts are bacteria that  can asymptomatically  colonise the human GIT, but possessing 
pro-inflammatory characteristics they might have a role in causing disease when, due to a 
dysbiosis, they increase in concentration (Cerf-Bensussan and Gaboriau-Routhiau, 2010). In 
the present study, members of the Enterobacteriaceae family, E. faecium, C. difficile and 
Campylobacter spp. were demonstrated to be enriched in the IBS microbiota, with respect to 
the faecal microbiota of healthy subjects. 
That the intestinal microbiota of subjects suffering from IBS deviates from the definition of a 
standard core microbiota in healthy conditions is a matter of fact, since an increasing number 
of studies evidenced peculiar modifications in the composition of the human intestinal 
microbial ecosystem correlated to health and disease status. However, the definitions of both 
IBS microbiota and standard core microbiota are challenged by the technological 
advancement, which is giving novel insights in understanding the dynamic interplay  of the 
microbial species thriving human gut. To date, a limited number of phylum- and group-level 
differences have been demonstrated comparing IBS patients to healthy subjects, whilst several 
alterations in abundance at genus and species level have been identified, leading to results that 
are sometimes controversial (Salonen et al., 2010).
In particular, our results are in accordance with those demonstrating an increase in abundance 
of Lactobacillus genus in IBS (Kassinen et al., 2007; Tana et al., 2010), which has been 
associated with augmented concentration of the organic acids propionate and acetate, that in 
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turn were correlated with abdominal pain, bloating and anxiety by Tana et al. (2010). 
Conversely, other studies indicated a depletion of lactobacilli as a characteristic of the IBS 
microbiota (Malinen et al., 2005; Kerchkoffs et al., 2009). Interestingly, a recent study 
performed using a DNA phylogenetic microarray by Rajilić-Stojanović  et al. (2011) 
demonstrated a trend similar to that reported in this study, in relation to the dynamics of the 
Bacteroides/Prevotella group and bacilli, with the first group depleted in subjects suffering 
from IBS and the second one increased in abundance in the IBS microbiota. We also 
demonstrated that  the IBS microbiota showed enrichment in bifidobacterial concentration, 
result which is in contrast with previous findings reporting decreased bifidobacterial 
concentrations in IBS patients (Kerckhoffs et al., 2009; Rajilić-Stojanović  et al., 2011). The 
HTF-Microbi.Array used in this study  targets the entire Bifidobacteriaceae family and the B. 
longum, B. adolescentis, B. breve and B. bifidum species.
Numerous human studies and clinical trials have investigated the therapeutic benefit of 
probiotics in alleviating the symptoms of IBS, with a wide range of formulations and 
microbial species tested. Commonly used probiotic strains belong to Bifidobacterium or 
Lactobacillus genera, whilst  less frequently used are strains of Propionibacterium 
freudenreichii, bacilli or yeasts (Wassenaar and Klein, 2008). Recently, we demonstrated in an 
in vitro study that K. marxianus B0399 possesses a number of beneficial properties, i.e. 
modulation of the immune response of PBMC and Caco-2 cells, impact on the metabolic 
activity of the intestinal microbiota and survival to simulated gastrointestinal environment, 
supporting its application as a probiotic (Maccaferri et al., 2012). The efficacy of a probiotic 
yoghurt including K. marxianus B0399 and B. animalis subsp. lactis Bb12 in the management 
of IBS has been investigated in an in vivo study (Lisotti et  al., 2011). The authors showed that 
these probiotics provoked an improvement in abdominal pain, bloating and bowel movement 
abnormality. 
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We characterised the intestinal microbiota of the 19 IBS patients enrolled in the above 
mentioned clinical study, with the aim of evaluating the impact of the probiotic administration 
on the IBS-associated unbalances of the intestinal microbiota.
Using both HTF-Microbi.Array and PCR-DGGE, we demonstrated that the supplementation 
of K. marxianus B0399 and B. animalis subsp. lactis Bb12 for 4 weeks did not modulate the 
composition of the microbiota in the IBS patients. Indeed, a marked inter-individual diversity 
was evident, since the majority of the samples before and after intervention clustered together, 
and no groupings according to the probiotic intervention were depicted. Similarly, Shannon 
and richness indices of DGGE gels were not modified by the 4-week probiotic administration. 
At the light of the most recent findings, our results are in agreement with an increasing 
number of studies demonstrating that probiotic administration is often not accompanied by 
compositional modulations of the intestinal microbiota in subjects suffering from IBS 
(Michail and Kenche, 2011), microbiota-mediated systemic disorders (Larsen et al., 2011) and 
in healthy conditions (Vitali et al., 2010).
In conclusion, we improved the knowledge about the peculiar modifications characterising the 
intestinal microbiota of subjects suffering from IBS. Furthermore, we demonstrated that the 
beneficial effects of the probiotic yoghurt containing K. marxianus B0399 and B. animalis 
subsp. lactis Bb12 are not associated to significant modifications of the human intestinal 
microbiota. These results open a new scenario about the necessity of characterising the 
mechanism of action of clinically relevant probiotic strains not only  towards the composition 
of the gut microbiota, but also taking into account its functionality. 
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POTENTIAL PREBIOTIC FLOURS FROM NATURAL SOURCES: 
IMPACT ON THE HUMAN GUT MICROBIOTA AND METABOLOME
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The gut microbiota is a complex and 
dynamic ecosystem that constantly  interacts 
with the human metabolism, endowing the 
host with physiological traits that have not 
evolved in the host (Gill et al., 2006; Neish 
et al., 2009; Hooper et al., 2002). In 
particular, the intestinal microbiota can be 
regarded as a virtual organ able to exert  a 
key  contribution to the human energy 
balance. Thus, the host can be considered a 
meta-organism, whose metabolism results 
from the both the human and the collective 
microbial community counterparts (Kau et 
al., 2011). Diet is considered a major driver 
for changes in the compositional and 
functional relationship between microbiota 
and the host. In fact, dietary components are 
susceptible for metabolism by the intestinal 
m ic rob i a l e cosys t em, pa r t i cu l a r ly 
influencing the growth and the metabolic 
activity of the dynamic bacterial populations 
thriving in the human colon (Laparra and 
Sanz, 2010). 
To date, dietary  fibres and prebiotics 
represent a useful dietary approach for 
influencing the composition of the human 
gut microbial community, since they are not 
completely metabolised by the digestive 
enzymes in the human small intestine. In 
particular, prebiotics are non-digestible food 
ingredients which are fermented by the gut 
microbiota and beneficially affect the host 
stimulating growth and/or activity  of 
specific intestinal bacteria (Gibson et al., 
2004). Most common prebiotics are non-
digestible GOS and FOS, such as inulin and 
oligofructose. Inulin-type fructans are 
present  in a range of different plants 
including wheat, onion, banana, garlic, leek 
and agave (Candela et al., 2010). 
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The biological effect of prebiotics mainly depends on their influence on the gut microbiota 
composition and metabolism, exerted through a number of different functional properties, 
such as prevention of pathogen adhesion and colonization, modulation of bowel habits, 
regulation of lipid and glucose metabolism and influence of the intestinal 
metabolome (Candela et al., 2010; Sherman et al., 2009). Several dietary fibers, including 
non-starch polysaccharides, whole-grain, cellulose, dextrans, chitins, pectins, β-glucans and 
waxes have been reported to potentially  provide similar beneficial effects as those of inulin-
type fructans (Laparra and Sanz, 2010; Costabile et al., 2008; Napolitano et al., 2009). Very 
recently, it has been demonstrated that prebiotic-enriched pasta could be a useful dietary tool 
to manipulate gut microbiome-mediated well-being endpoint (Russo et al., 2010; Russo et al., 
2011).
BOX N. 5 - METABOLOMICS AND DIET: FEEDING THE KNOWLEDGE
Whereas the inter-individual diversity  in composition of the human gut microbiota is 
large and commonly  accepted, differences in the colonic metabolome has been found 
to originate mainly  from variable metabolite concentrations, rather than from individual 
differences in the diverse composition of the metabolome. To date, 1H-NMR, GC-MS 
and LC-MS methods have been set up in order to monitor changes in gut metabolome 
in response to exogenous stimuli. 
SCFAs and organic acids are the main microbial metabolites detected in the faecal 
metabolome, using targeted GC-MS. Conversely, untargeted NMR-based metabolite 
profiling is a rapid, comprehensive technique which allow  to detect a variety of 
different fermentation products in faeces, which include SCFAs, organic acids (i.e., 
succinate, pyruvate, fumarate, lactate), amino acids, uracil, trimethylamine, ethanol, 
glycerol, glucose, phenolic acids, cholate and lipid components. 
Recently, NMR-based metabolomics platforms have been developed to study  the 
impact of non-digestible food ingredients in the colonic metabolome. Metabolomic 
profiling might reveal new  affected metabolic pathways useful in discovering potential 
biomarkers of metabolic activity of dietary fibres, prebiotics, or probiotics.
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In the present study, we aimed at  investigating the impact of four flours characterised by  a 
naturally  high content in dietary fibres [Wholegrain rye (WGR), Nutriwheat (wholegrain 
wheat, NW), Pulses (chickpeas and lentils 50:50, PF), Barley milled grains (BMG)] on the 
human intestinal microbial ecosystem, using an in vitro three-stage continuous culture system 
simulating the human large intestine, which represents a relevant  tool for monitoring the 
ecology and metabolic activities of colonic microbiota in relation to different external 
perturbations (Macfarlane et al., 1998; Macfarlane et al., 2011). 
Main bacterial groups of the faecal microbiota were evaluated during the colonic model 
system study using the 16S rRNA-based FISH approach. Potential effects of supplementation 
of the four flours on the microbial physiology were studied using NMR-based metabolomics 
in combination with multivariate pattern recognition techniques (Bertini, et al., 2009; Bernini 
et al., 2011; Bertini et  al., 2012). Finally, the ability of the metabolites of the cultural 
supernatants from the colonic model system, before and after the dietary supplementation, to 
modulate the growth of human intestinal epithelial cells was assessed using a HT29 cell-
growth curve assay.
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Substrates and simulated in vitro 
human digestion 
Four different flours (WGR, NW, PF, 
BMG), whose nutritional profile was 
characterised by official reference methods 
(ashes: UNI ISO 2171; proteins: UNI 10274 
831/12/93 and ISO 1871 (15/12/75); total 
dietary fibre: AOAC 985,29; RS: AOAC 
2002.02; β-glucans: AOAC 995.16 2005; 
FOS: AOAC 997.08 and GOS: AOAC 
2001.02), were selected considering their 
different  composition and potential 
functional properties (Table 5). Prior to 
being added into the colon model system, 
the flours were digested in vitro under 
appropriate conditions according to the 
procedures described by  Mills et al. (2008). 
Gastric and small intestinal environments 
were resembled using appropriate enzymatic 
concentration of HCl and pepsin, as well as 
bile salts and pancreatic enzymes, 
respectively. Dialyses with membrane of 
100-200 Daltons cut off (Spectra/por 
100-200 Da MWCO dialysis membrane, 
Spectrum Laboratories Inc.) were used to 
remove the monosaccharide from the pre-
digested flours. 
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Flour Ashes Proteins Sugars TDF RS β-glucans FOS GOS
Wholegrain rye 1.55 8.91 1.91 18.04 < 0.20 1.89 4.50 1.53
Pulses 3.02 22.95 1.78 15.44 2.00 < 0.20 0.70 6.50
Nutriwheat 7.30 22.92 2.48 26.77 < 0.20 1.22 2.3 1.0
Barley milled 
grains 1.64 11.61 4.08 20.93 0.21 8.14 1.2 0.61
Three-stage continuous culture gut model system
The three-stage continuous culture model of the human colon comprised of 3 glass fermenters 
of increasing working volume, simulating the proximal (V1, 280 mL), transverse (V2, 300 
mL) and distal colon (V3, 320 mL). The 3 fermenters connected in series were kept at 37 °C, 
pH was maintained at 5.5 (V1), 6.2 (V2) and 6.8 (V3) and anaerobic conditions were 
introduced by  continuously sparging with O2-free N2. V1 was fed by  means of a peristaltic 
pump with CMGM (Macfarlane et al., 1998). Human faecal samples were collected on site, 
kept in an anaerobic cabinet (10% H2, 10% CO2, 80% N2) and used within a maximum of 15 
min after collection. This experiment was carried out in duplicate using faecal samples from 
two different healthy  volunteers (1 male aged 31 and, 1 female; aged 31-38 years old). None 
of the volunteers had received antibiotics or probiotics for at least 3 months before sampling. 
A 1:5 (w/w) faecal dilution in anaerobic PBS [0.1 M PBS (pH 7.4)] was prepared and the 
samples homogenized in a stomacher (Seward, Worthing) for 2 min. Each stage of the colonic 
model was inoculated with 100 mL faecal slurry. Total system transit time was set at 48 h, 
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Table 5. Composition and nutritional profile of the four selected flours used in this 
study. Data are expressed as percentage of the total nutritional composition. TDF: 
Total dietary fibres; RS: Resistant starch.
according to mean retention time of healthy individuals. Following inoculation, the colonic 
model was run as a batch culture for a 24 h period in order to stabilise bacterial populations 
prior to the initiation of medium flow. After 24 h (T0) the medium flow was initiated and the 
system ran for 8 full volume turnovers to allow for steady state to be achieved (SS1). Taking 
into account the operating volume (900 mL) and the retention time (48 h) of the colonic 
model system, dialysis retentate of the tested flours were added daily  into V1 at 1% (w/v). 
The tested flours were added to the system as described for a further 8 volume turnovers upon 
which steady  state 2 (SS2) was achieved. Each steady  state was confirmed through sampling 
on three consecutive days for SCFAs and FISH analyses. 
Sample collection and preparation
Samples for FISH were immediately fixed in 4% paraformaldehyde as previously described 
(Martín-Peláez et al., 2008). 
Samples for HT29 cell growth curve analysis were centrifuged at  12,000 x g for 15 min and 
supernatants were sterile filtered and frozen immediately. 
Samples for metabolomics analysis were homogenised at high speed in a mechanical 
homogeniser (MiniLab 8.30H, Rennie) for 30-45 s, further subjected to two cycles of freezing 
and thawing to breakdown cell membranes and release cytoplasmic metabolites, and finally 
centrifuged at 10,000 x g for 15 min at 4 °C. Supernatants were collected and stored at -80 °C 
until measurement. 
In vitro enumeration of bacterial population by FISH
Numbers of the main intestinal bacterial groups, as well as total bacterial populations, was 
evaluated in samples from the colonic model system by FISH analysis, as previously 
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described by Martín-Peláez and colleagues. The probes used are reported in Annex 1 and 
were commercially synthesised and 5’-labelled with the fluorescent Cy3 dye (Sigma). 
Modulation of HT29 cell growth by the tested flours
The influence of the colonic model supernatants, recovered before and after the 
supplementation of the four tested flours, on the growth and survival of the human colon 
carcinoma cell line HT29 was determined using the growth curve assay, as previously 
described by  Maccaferri et al. (2010). Results are expressed as EC50, which represents the 
effective concentration of colonic model supernatants resulting in a 50% reduction of cell 
number under the specified cell culture and treatment conditions compared to the growth of 
untreated cells. 
NMR profiling
Frozen samples were thawed at room temperature and centrifuged at 16,000 x g for 5 min. A 
total of 300 µl of a sodium phosphate buffer (70 mM Na2HPO4; 20% (v/v) 2H2O; 6.15 mM 
NaN3; 6.64 mM TMSP (pH 7.4) was immediately  added to 300 µl of each sample, and the 
mixture homogenised by  vortexing for 30 s. NaN3 was added to ensure that metabolites are 
not generated or consumed via the action of bacteria or bacterial enzymes during the time of 
NMR sample preparation and NMR spectra acquisition. A total of 450 µl of this mixture was 
transferred into a 4.25 mm NMR tube for analysis.
NMR spectra for all samples were acquired using a Bruker spectrometer (Bruker Biospin) 
operating at 14.1 T (600.13 MHz proton Larmor frequency) equipped with a CPTPI 
cryoprobe, an automatic tuning-matching unit and an automatic sample changer. A BTO 2000 
thermocouple served for temperature stabilisation at  the level of approximately  0.1 K at the 
sample. Before measurement, samples were kept for at least 3 min inside the NMR probe-
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head, for temperature equilibration (27 °C). For each sample, a mono-dimensional (1D) NMR 
spectrum was acquired with water peak suppression using a standard pulse sequence (Bruker 
terminology: noesygppr1d.comp) (Le Gall et al., 2011), 64 scans, 96 k data points, a spectral 
width of 18028 Hz, and a relaxation delay of 4 s. Free induction decays were multiplied by an 
exponential function equivalent to a 1.0 Hz line-broadening factor before applying Fourier 
transform. Transformed spectra were corrected for phase and baseline distortions and 
calibrated (proton signal of TMSP at 0.00 ppm) using TopSpin (Version 2.1; Bruker BioSpin). 
The regions between 5.0 and 4.5 ppm, which contain the residual water signal, were removed 
from the subsequent analysis. Each 1D spectrum in the range between 0.2 and 10.0 ppm was 
segmented into 0.02-ppm chemical shift bins, and the corresponding spectral areas were 
integrated using AMIX software (Version 3.8.4; Bruker BioSpin) giving a total of 466 
variables. The total spectral area was calculated on the remaining bins and normalisation on 
the total area was carried out  on the data prior to pattern recognition. All metabolites of 
interest were then checked and their NMR signals were assigned on template 1D NMR 
profiles by using matching routines of AMIX 3.8.4 (Bruker BioSpin) in combination with the 
BBIOREFCODE (Version 2.0.0; Bruker BioSpin) reference databases and published literature 
(Le Gall et al., 2011; Wu et al., 2010; Bezabeh et al., 2009; Hong et al., 2011; Martin et al., 
2010).
Statistical analysis
Bacterial counts and HT29 growth modulation data were analysed by  one-way  ANOVA, 
using Tukey’s post-test analysis when the overall P value of the experiment was below the 
value of significance (P < 0.05). An additional paired t-test was applied in order to assess the 
significance of results of single pairs of data. Analyses were performed using GraphPad Prism 
5.0 (GraphPad Software, La Jolla, CA, USA). Metabolomic fingerprint-based data analysis 
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was carried out  using R software with scripts developed in-house. Data were normalised to 
the total area and mean-centred before analysis (separately  for each vessel). PCA was 
conducted in order to observe intrinsic clusters and a general overview of the variance of the 
NMR profiles. Furthermore, NMR spectra were subjected to O-PLS for highlighting the 
effects of the four different flours. O-PLS is an extension of the Partial Least Square 
regression method (Wold et  al., 1984), featuring an integrated Orthogonal Signal Correction 
filter (Wold et al., 1998). The relative concentrations of the metabolites were calculated by 
integrating the signals in the spectra normalized to the total area. To evaluate the effects of 
different flours in the three vessels, the relative concentrations of the metabolites were mean 
centred (separately for each vessel). Statistical significance was assessed using univariate 
nonparametric Wilcoxon rank-sum test between SS1 and SS2 samples of each treatment. 
When P < 0.05, differences among samples were considered statistically significant. 
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Impact  of the flours on the human 
colonic microbiota
Annex 4 describes the impact of the four 
flours on the composition of the main 
bacterial groups constituting the core 
colonic microbiota. 
A number of significant modifications along 
the study have been shown for all the tested 
flours. In particular, WGR mediated a 
significant increase in concentration of 
B i f i d o b a c t e r i u m g e n u s , L A B a n d 
Desulfovibrionales spp. in all the stages of 
the colonic model system, whereas 
Roseburia/E. rectale group significantly 
decreased in V1, simulating the proximal 
colon, after the administration of this flour. 
Similarly, NW induced a significant increase 
in LAB in the first stage of the colonic 
model system, bifidobacteria in the second 
stage, simulating the transverse colon, and 
Desulfovibrionales spp. in the third stage, 
simulating the distal colon. A decrease in 
concentration of Ruminococcus spp. was 
further found in the whole colonic model 
system. 
While modulating an overall increase of 
Bacteroides/Prevotella and a decrease of 
Roseburia/E. rectale group in the entire 
colonic model system, the supplementation 
of PF provoked several modifications in 
each region of the fermentative system: in 
V1, a decrease of E. rectale/Clostridium 
cluster XIVa group  and Atopobium cluster, 
as well as a decrease of Clostridium cluster 
IX in V2, an increase of Ruminococcus spp. 
in V3 and a decrease of F. prausnitzii in V2 
and V3 were demonstrated. 
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Finally, BMG provoked a decrease in E. rectale/Clostridium cluster XIVa group in the third 
stage of the colonic model system and Roseburia/E. rectale groups in the second and third 
stage. An increase of Desulfovibrionales spp. was concomitantly shown in the V1 and V2 
when BMG was used as dietary flour. 
HT29 growth modulation by the colonic model system supernatants
EC50 was used to compare the effect of colonic model supernatants, before and after the 
administration of the four different flours, on HT29 cell growth (Fig. 22). No significant 
changes between EC50(SS1) and EC50(SS2) were found in the all the stages composing the 
colonic model system, at SS1 and SS2, for any of the four tested dietary flours.
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Figure 22. Effect of supernatants recovered from Vessel 1, Vessel 2, and Vessel 3 
of the colonic model system, on HT29 growth before (SS1) and after (SS2) 
administration of the four dietary flours. Growth inhibition was assessed by co-
incubating HT29 cells with increasing concentration (0%, 1%, 2.5%, 5%, 10%) of 
fermentation supernatants followed by DAPI staining. Results are expressed as 
means of relative HT29 cell growths (%) ± SEM of 2 colonic models with two 
independent sampling times each. For each colonic model and time point 
measurements were performed in triplicate. Figure shows the comparison of EC50 
values in SS1 and SS2 for each vessel, for each of the four flours. 
NMR analysis
The comparison of the NMR spectra (Figure 23) of samples from the colonic model at SS1 
and SS2 samples (Table 6) demonstrated that all the tested dietary  flours caused different 
modifications in metabolite concentrations. In particular, BMG and PF induced several 
changes in the metabolic profile. After the supplementation of BMG and PF, colon model 
metabolome was characterised by lower level of trimethylamine and higher level of acetate. 
In addition, PF provoked a decrease in levels of butyrate and isovalerate, whilst higher levels 
of propionate and tyrosine were found. Similarly  to PF, NW induced lower level of butyrate 
and higher level of propionate. Interestingly, WGR induced a decrease in methanol not 
observed with any other flour.
PCA was performed to obtain a simplified view of the variation in the data and to understand 
the global metabolic changes in the three stages of the colon model. Two PC were calculated, 
PC1 and PC2, which explain 60.7% and 19.4% of the total variance, respectively. Scores 
along PC1 and PC2 showed a strong separation among the V1 samples and the V2 and V3 
samples, as reported in Figure 24A. The outlier, found in the PCA plot, was due to the 
presence of a high concentration of lactate.  O-PLS analysis was also performed on NMR 
profiles using as supervisory variable the different dietary  interventions undertaken in the 
study (Figure 24B). This analysis demonstrated that the effect of PF and BMG 
supplementation on the on overall colonic metabolome was higher than that resulting from 
administration of NW and WGR. 
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Figure 23. Spectral region 1.50–4.50 ppm of high resolution proton NMR 600 MHz 
spectra acquired with a 1D standard experiment from colonic model supernatants.
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Compound Pulses (PF)
Barley milled 
grains (BMG)
Nutriwheat 
(NW)
Wholegrain rye 
(WG)
Acetate ↑ 4.33 · 10-3 ↑ 2.16 · 10-3 ↓ 8.18 · 10-1 ↑ 5.89 · 10-1
Alanine ↑ 6.49 · 10-2 ↓ 6.99 · 10-1 ↓ 6.99 · 10-1 ↑ 5.89 · 10-1
Butyrate ↓ 2.16 · 10-3 ↓ 2.40 · 10-1 ↓ 8.66 · 10-3 ↑ 6.99 · 10-1
Ethanol ↑ 6.99 · 10-1 ↑ 3.10 · 10-1 ↓ 3.10 · 10-1 ↓ 5.89 · 10-1
Formate ↓ 6.99 · 10-1 ↓ 8.18 · 10-1 ↓ 9.37 · 10-1 ↑ 1.32 · 10-1
Fumarate ↑ 6.99 · 10-1 ↑ 3.94 · 10-1 ↑ 1.00 · 10-0 ↑ 2.40 · 10-1
Isoleucine ↑ 3.10 · 10-1 ↓ 1.32 · 10-1 ↑ 3.10 · 10-1 ↑ 9.37 · 10-1
Isovalerate ↓ 2.60 · 10-2 ↑ 9.37 · 10-1 ↓ 9.37 · 10-1 ↑ 5.89 · 10-1
Lactate ↑ 6.99 · 10-1 ↑ 1.00 · 10-0 ↓ 3.94 · 10-1 ↑ 2.40 · 10-1
Leucine ↑ 3.94 · 10-1 ↓ 6.99 · 10-1 ↑ 2.40 · 10-1 ↑ 8.18 · 10-1
Lysine ↑ 1.32 · 10-1 ↑ 9.37 · 10-1 ↑ 2.16 · 10-3 ↓ 6.99 · 10-1
Methanol ↑ 1.80 · 10-1 ↓ 3.94 · 10-1 ↓ 5.89 · 10-1 ↓ 2.16 · 10-3
Phenylalanine ↑ 6.49 · 10-2 ↑ 3.10 · 10-1 ↑ 1.32 · 10-1 ↑ 1.00 · 10-0
Propionate ↑ 2.60 · 10-2 ↓ 1.00 · 10-0 ↑ 2.16 · 10-3 ↓ 3.10 · 10-1
Trimethylamine ↓ 4.11 · 10-2 ↓ 8.66 · 10-3 ↓ 1.80 · 10-1 ↓ 1.80 · 10-1
Tyrosine ↑ 4.11 · 10-2 ↑ 3.10 · 10-1 ↑ 1.32 · 10-1 ↓ 3.94 · 10-1
Uracil ↑ 9.37 · 10-1 ↑ 5.89 · 10-1 ↓ 1.52 · 10-2 ↓ 8.18 · 10-1
Valine ↑ 6.99 · 10-1 ↓ 6.49 · 10-2 ↑ 9.37 · 10-1 ↓ 8.18 · 10-1
Table 6. P Values of metabolites resulting from the comparison between control 
and different dietary interventions. Significant differences between SS1 and SS2 
are highlighted in bold and underlined.
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Figure 24. Multivariate analysis of 
1H-NMR spectra of faecal samples. 
(A) PCA scores plot coloured 
according to the vessel: dark grey 
Vessel 1, grey Vessel 2, and light 
grey Vessel 3. (B) O-PLS scores plot 
discriminating the effects of different 
probiotics. Circle SS1, square PF, 
rhombus BMG, triangle NW, inverted 
triangle WGR rye. 
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In recent  years, a new health paradigm has 
evolved, placing more emphasis on the 
beneficial aspects of diet. Although the 
primary role of diet is to provide nutrients to 
fulfil metabolic requirements, the use of 
foods to improve health and wellbeing is 
being increasingly accepted (Figueroa-
Gonzalez et al., 2011).
Dietary fibres and prebiotics can be included 
in a wide range of foods, such as bakery, 
dairy  and beverage products. In particular, 
prebiotics are oligosaccharides or more 
complex saccharides that are selectively 
metabolised by some commensal groups, 
including those considered to be beneficial 
for the host, thus impacting on the gut 
microbiota composition and functional 
activity (Sherman et al., 2009; Laparra and 
Sanz, 2009).
Cereal grains can contain naturally 
occurring oligosaccharides such as 
galactosyl derivatives of sucrose stachyose 
and raffinose and fructosyl derivatives of 
sucrose. Furthermore, cereal grains and 
pulses contain dietary fibre, which 
encompasses a heterogeneous range of 
complex polysaccharides that are not 
substantially  digested in the small intestine 
and pass through to the colon. Therefore, 
dietary fibre constitutes a potential and not 
yet fully explored source of prebiotics from 
cereals and legumes (Charalampopoulos et 
al., 2002). 
In the perspective of designing foods from 
natural sources and more effective dietary 
strategies for human health promotion, here 
we studied the putative prebiotic potential of 
four flours, which are naturally rich in fibre, 
by assessing their impact on the human 
intestinal microbial ecosystem. 
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The four tested flours belong to two different categories, cereal grain flours, namely 
wholegrain rye, wholegrain wheat and barley  milled grains, and pulses flour, which are not 
yet evaluated for their prebiotic potential. In particular, the two wholegrain flours, one 
deriving from rye and one from wheat, contain naturally high concentrations of GOS and 
FOS, whilst the pulses flour, composed by a mix of lentils and chickpeas 50:50, is particularly 
rich in GOS and RS. Finally, the barley milled grains flour is a rich source for β-glucans.
β-glucans are components of dietary cereals that are becoming increasingly  recognized as 
functional ingredients in food and drink products (Naumann et al., 2006). Mixed-linkage β-
glucans, present at high levels in the BMG flour, have been demonstrated to evoke a range of 
metabolic and physiological responses, as lowering cholesterol levels and insulin responses 
(Naumann et al., 2006; Kerckhoffs et al., 2003). In the present study, an increase in acetate, 
following BMG administration in the colon model system, has been demonstrated. Our results 
support positive modulation of SCFA by barley, as previously reported by  Hughes et al. 
(2008), who evaluated the in vitro fermentation of barley-derived β-glucans by the human 
faecal microbiota, demonstrating a significant increase in propionate. Notably, we 
demonstrated a decrease in the concentration of trimethylamine, a precursor of the 
trimethylamine N-oxide. This harmful compound, produced by commensal inhabitants of the 
intestinal microbiota, has been demonstrated to play a role in the atherogenesis (Loscalzo, 
2011).
Pulses contain a number of bioactive substances including enzyme inhibitors, lectins, 
phytates, oligosaccharides and phenolic compounds. These polyphenolic compounds consist 
mainly of tannins, phenolic acids and flavonoids (Campos-Vega et al., 2009). Phenolics are 
metabolized by the gut microbiota, affecting intestinal health (Selma et al., 2009). In addition, 
chickpeas, which contain significant levels of oligosaccharides, non-starch polysaccharides, 
RS and resistant protein can exert a not yet fully  explored prebiotic potential (Sanchez-Mata 
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et al., 1998). Here, we demonstrated that PF induces an extensive modulation of the colonic 
metabolome, provoking an increase in concentration of acetate and propionate, as well as a 
decrease of butyrate and branched-chain fatty acid iso-valerate. This metabolic shift can be 
explained by the overall increase of Bacteroides/Prevotella species, known to be primary 
propionate and acetate producers, which are representing a considerable share of the intestinal 
microbiota resulting from the supplementation with PF. Conversely, the decrease of major 
butyrate-producers as Clostridium cluster IV and XIVa can be related to the decrease of 
butyrate (Charalampopoulos and Rastall, 2009). Notably, propionate is a major microbial 
fermentation metabolite in the human gut with well-known health effects not only at colon 
level, but also in a broader human body context. In fact, propionate is thought to lower 
lipogenesis and serum cholesterol level, as well as to play a role in weight control by 
stimulating satiety (Hosseini et al., 2011).
Wholegrain has been extensively  studied for its beneficial effects and several epidemiological 
studies have shown its protective activity  against cancer, diabetes, obesity and CVD (Katcher 
et al., 2008; Slavin, 2004). However, little is known about peculiar modulation of the colonic 
microbiota related to wholegrain rye and wheat. In the present study, we have demonstrated 
that WGR impacts on the colonic microbiota, eliciting an increase in concentration of 
bifidobacteria, lactobacilli and Desulfovibrionales, whilst  a decrease in Roseburia genus was 
observed. Similarly, NW caused significant yet less pronounced increase of bifidobacteria, 
LAB and Desulfovibrionales in comparison with WGR, whereas a decrease of ruminococci 
was further demonstrated. These data are in accordance with those of Costabile et al. (2008), 
who for the first time broadly investigated the impact of wholegrain on the human colonic 
microbiota. In particular, these authors found significant increases in lactobacilli/enterococci 
after the ingestion of either wheat bran or wholegrain but in Bifidobacterium spp. only after 
wholegrain consumption. 
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The supplementation of wholegrain-based flours (WGR and NW) induced modulation of the 
colonic metabolome. Indeed, we demonstrated a decrease in the concentration of methanol, a 
compound that has been previously demonstrated to increase in a number of pathological 
conditions, especially in subjects affected by  Campylobacter jejuni and ulcerative colitis 
(Garner et al., 2007). A decrease in methanol concentration related to a modulation of the 
colonic microbiota towards a more bifidogenic structure has been reported in literature. In 
fact, a decrease in this alcohol has been associated with positive and bifidogenic modulation 
of the colonic microbiota of patients affected by  Crohn’s diseases after treatment with the 
antibiotic rifaximin (Maccaferri et al., 2010). Conversely, no significant changes in 
concentrations of the SCFAs acetic, propionic, butyric or caproic acids were observed in 
response to WGR administration. 
NMR analysis of the colon model metabolome following the NW administration depicted a 
different scenario. NW is mediating a decrease of butyrate and an increase of propionate and 
the essential amino acid lysine. Notably, the decrease in concentration of butyrate could be 
explained by a depletion of Ruminococcus spp. after the supplementation of the wholegrain 
wheat flour, since ruminococci are well-known to produce butyrate (De Vuyst et al., 2011).
Growth inhibition of colon carcinoma cells, differentiation and apoptosis are thought to be 
mechanisms by which dietary fibre exerts a chemopreventive effect in the colon (Lupton, 
2004). However, the administration of all the four flours from natural sources did not 
influence the growth-modulatory potential of the supernatants recovered from the three stages 
of the colonic model system. Since it has been demonstrated that the concentration of butyrate 
in fermentation supernatants from colonic model systems was directly  associated with their 
growth inhibitory potential (Klinder et  al., 2004), our observations in the HT29 growth assay 
are in accordance with the NMR results showing that the concentration of butyrate in the 
supernatants did not change or even decreased after administration of the flours. In 
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conclusion, wholegrain rye and wheat, pulses and barley milled grain flours showed peculiar 
and positive modulations of the intestinal microbiota composition and its small molecule 
metabolome. Therefore, our results could support the utilisation of these ingredients in the 
development of a variety of potentially  prebiotic food products aimed at improving 
gastrointestinal health.
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CHAPTER 6 - CONCLUDING REMARKS
The utilisation of probiotics and prebiotics to promote human health is increasing, and a solid 
scientific substantiation of the health claims associated to this food ingredients has to be 
generated in order to develop new functional foods is required. 
In this study, we extensively evaluated the potential probiotic yeast  K. marxianus B0399. We 
presented a combined in vitro and in vivo approach for the evaluation of the beneficial 
activities of the novel probiotic strain K. marxianus B0399, which included a preliminary 
broad investigation of the intrinsic characteristics of the yeast, followed by a human pilot 
study for evaluating its impact on the human intestinal microbiota. 
We demonstrated that K. marxianus B0399 possesses a number of beneficial and strain-
specific properties, which are desirable in a microorganism to be considered for application as 
a probiotics, i.e. strong adhesion to intestinal epithelial cells, immune modulation and impact 
on the composition of the colonic microbiota. Furthermore, we demonstrated that unbalances 
in the composition of the intestinal microbiota of subjects suffering from IBS are not 
counterbalanced by the administration of a probiotic yoghurt containing K. marxianus B0399 
and B. animalis subsp. lactis Bb12. However, the administration of the diary  probiotic 
formulation investigated in the present study has been demonstrated to be beneficial in the 
management of IBS symptoms. Therefore, these findings enforce the necessity of 
characterising the mechanism of action of clinically relevant probiotic strains not only 
towards the composition of the gut microbiota, but also taking into account its functionality.
Besides probiotics, prebiotics are gaining a relevant role in the dietary promotion of human 
health, due to their ability to influence the symbiotic intestinal microbiota. In the perspective 
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of designing foods from natural sources and more effective dietary strategies for human 
health promotion, in the present study we further investigated studied the putative prebiotic 
potential of three cereal grain flours and one pulses flour.
Combining a molecular and cellular approach with cutting-edge metabolomics methods, we 
demonstrated that wholegrain rye and wheat, pulses and barley milled grain flours showed 
different and peculiar positive modulations of the intestinal microbiota composition and its 
small molecule metabolome. Therefore, our results could support the utilisation of these 
ingredients in the development of a variety of potentially prebiotic food products to be tested 
in vivo for substantiating claims on the gastrointestinal health promotion.
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Annex 1. Oligonucleotide probes used in this study for FISH analysis.
Target genus or group Probe Sequence (5’ to 3’)
Most Bacteria EUB338a GCTGCCTCCCGTAGGAGT
Most Bacteria EUB338IIa GCAGCCACCCGTAGGTGT
Most Bacteria EUB338IIIa GCTGCCACCCGTAGGTGT
Atopobium, Colinsella, Olsenella and 
Eggerthella spp.; Cryptobacterium 
curtum; Mycoplasma equigenitalium 
and Mycoplasma elephantis
Ato291 GGTCGGTCTCTCAACC
Most Bacteroides sensu stricto and 
Prevotella spp.; all Parabacteroides; 
Barnesiella viscericola and Odoribacter 
splanchnicus
Bac303 CCAATGTGGGGGACCTT
Most Bifidobacterium spp Bif164 CATCCGGCATTACCACCC
Most Deltaproteobacteria and most 
Gemmatimonadetes DELTA495a
b AGTTAGCCGGTGCTTCCT
Some Deltaproteobacteria DELTA495bb AGTTAGCCGGCGCTTCCT
Some Deltaproteobacteria DELTA495cb AATTAGCCGGTGCTTCCT
Most members of Clostridium cluster 
XIVa; Syntrophococcus sucromutans, 
[Bacteroides] galacturonicus and 
[Bacteroides] xylanolyticus, 
Lachnospira pectinschiza and 
Clostridium saccharolyticum
Erec482 GCTTCTTAGTCARGTACCG
Faecalibacterium prausnitzii and 
related sequences Fprau655 CGCCTACCTCTGCACTAC
Most Lactobacillus, Leuconostoc and 
Weissella spp.; Lactococcus lactis; all 
Vagococcus, Enterococcus, 
Melisococcus, Tetragenococcus, 
Catellicoccus, Pediococcus and 
Paralactobacillus spp.
Lab158# GTATTAGCAYCTGTTTCCA
Most members of Clostridium cluster I; 
all members of Clostridium cluster II; 
Clostridium tyrobutyricum; 
Adhaeribacter aquaticus and 
Flexibacter canadensis (family 
Flexibacteriaceae); [Eubacterium] 
combesii (family Propionibacteriaceae)
Chis150 TTATGCGGTATTAATCTYCCTTT
Clostridium cluster IX Prop853 ATTGCGTTAACTCCGGCAC
Roseburia subcluster Rrec584 TCAGACTTGCCG(C/T)ACCGC
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Target genus or group Probe Sequence (5’ to 3’)
Most Desulfovibrionales DSV567 TACGGATTTCACTCCT
Clostridium sporosphaeroides, 
Ruminococcus bromii, Clostridium 
leptum
Rbro730c # TAAAGCCCAGCYAGGCCGC
Ruminococcu salbus, Ruminococcus 
flavefaciens Rfla729
c # AAAGCCCAGTAAGCCGCC
a, b, c These probes were used in equimolar concentrations
# These probes were used following pre-treatment with Lysozyme (100U; 20 µL of 1 
mg/mL solution of 50,000 U/ mg protein)
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Annex 2. Sequence of the excised and re-amplified band referred to K. marxianus
TCAAACTGTTAAAAAATAACTGGGTTCCTCGCCaCACGGGATTCTCACCCTCTATGA
CGTCCTGTTCCAGGAACATAGACAAGGACGAGCTACAAAGTCGCCTTCTTCAAAT
TACAACTCGGACGTCGAAGACGCCAGATTTCAAATTTGAGCTTTTGCCGCTTCACT
CGCCGTTACTAAGGCAATCCCGGTTGGTTTCTTTTCCTCCGCTTATTGATATGGCCC
GCCGCCGGCTCGCGCGTCCCGGCGGTCGCGCGGCCCGCA
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Annex 3. Data of relative abundance of main bacterial groups targeted by HTF-
Microbi.Array in subjects suffering from IBS and healthy individuals. Data are 
expressed as percentage of each bacterial group on the total targeted microbiota
Index Bacterial group/species Index Bacterial group/species
1 B. longum 18 B. breve
2 Y. enterocolitica 19 B. adolescentis
3 Proteus spp. 20 B. bifidum
4 Campylobacter spp. 21 B. clausii
5 B. cereus 22 L. plantarum
6 B. subtilis 23 L. buchnerii
7 E. faecalis 24 Clostridium cluster I-II
8 E. faecium 25 Clostridium cluster XI
9 L. casei 26 Clostridium cluster IX
10 L. salivarius 27 R. bromii
11 Fusobacterium spp. 28 R. albus
12 Bacteroides/Prevotella 29 F. prausnitzii
13 C. perfringens 30 O. guillermondii
14 C. difficile 31 Cyanobacteria spp.
15 E. rectale 32 Lactobacillaceae
16 Veillonella spp. 33 Enterobacteriaceae
17 Clostridium cluster XIV 34 Bidifobacteriaceae
Subjects suffering from IBS, enrolled in the study:
1 2 3 4 5 6 7 8 9
201_t0 1.39 1.34 1.43 1.11 1.27 1.15 1.29 1.09 1.08
201_t1 0.67 0.85 1.01 0.96 0.92 0.66 0.77 0.71 0.62
27_t0 1.02 0.94 0.87 0.81 0.99 0.91 1.00 0.86 0.86
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1 2 3 4 5 6 7 8 9
27_t1 0.98 1.04 1.06 1.03 1.28 0.98 1.01 1.19 1.08
28_t0 1.14 1.08 1.08 1.17 1.36 1.37 1.02 0.91 0.94
28_t1 1.00 0.83 0.83 0.66 1.16 0.72 1.07 0.72 0.67
31_t0 0.66 0.81 1.93 0.63 0.93 1.21 1.87 0.60 0.68
31_t1 0.33 0.44 2.95 0.33 0.38 2.69 1.75 0.29 0.29
32_t0 0.83 1.31 0.87 0.63 1.37 0.75 0.68 0.69 0.76
32_t1 0.64 1.41 1.05 0.70 2.49 0.86 0.70 0.57 0.51
33_t0 1.25 1.33 0.97 0.88 1.30 0.83 0.96 1.18 0.90
33_t1 0.96 0.93 0.59 0.51 0.96 0.50 0.57 0.51 0.63
34_t0 0.58 0.77 0.97 0.63 0.96 0.67 0.73 0.75 0.65
34_t1 0.68 0.79 0.87 0.74 1.18 1.02 0.76 0.67 0.65
35_t0 0.77 0.93 1.02 0.96 0.96 0.74 0.73 0.84 0.81
35_t1 0.76 0.88 0.86 0.69 0.74 0.77 0.70 0.71 0.67
37_t0 0.50 0.57 0.56 0.38 1.23 0.66 0.48 0.58 0.38
37_t1 0.50 1.75 0.66 0.37 1.59 0.41 0.40 0.54 0.64
59_t0 0.60 0.47 2.53 0.24 0.61 2.09 0.96 1.11 0.24
59_t1 0.97 1.24 1.06 0.75 1.80 0.77 0.75 0.65 0.70
63_t0 1.06 0.59 2.05 0.26 0.60 1.29 1.02 1.61 1.99
63_t1 0.24 0.81 0.71 0.67 1.66 1.63 0.51 0.45 0.69
65_t0 0.58 0.56 0.49 0.39 0.99 0.44 0.68 0.63 0.54
65_t1 0.90 1.51 1.07 0.70 1.42 0.73 2.21 0.79 1.02
66_t0 0.26 0.21 2.02 0.60 0.17 1.45 1.48 1.10 0.17
66_t1 1.76 1.56 1.50 1.28 2.07 1.41 1.34 1.25 1.30
78_t0 0.67 0.64 0.78 0.56 0.65 0.71 0.63 0.71 0.60
78_t1 1.77 2.07 1.73 1.55 1.80 2.03 1.81 1.60 1.66
80_t0 0.24 0.32 1.76 0.25 0.24 1.42 1.33 0.27 0.17
80_t1 0.65 0.74 0.70 0.55 0.84 0.66 0.59 0.59 0.60
82_t0 1.17 1.56 1.18 1.13 1.27 1.17 1.42 1.24 1.22
82_t1 0.97 1.29 1.18 0.92 1.15 1.02 0.94 1.00 0.96
83_t0 0.95 1.35 1.02 0.37 1.33 1.29 0.74 1.09 0.25
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1 2 3 4 5 6 7 8 9
83_t1 1.18 0.98 1.80 1.00 1.23 0.58 0.40 1.69 0.23
84_t0 0.67 1.39 1.30 0.59 2.41 0.89 0.64 0.64 0.60
84_t1 1.02 1.67 1.59 0.76 2.14 1.06 0.90 0.96 0.90
89_t0 0.89 0.90 0.58 0.61 1.16 0.67 0.54 0.72 0.72
89_t1 2.00 1.99 1.87 1.27 2.80 1.46 1.84 1.17 1.13
10 11 12 13 14 15 16 17 18
201_t0 3.57 1.59 11.24 1.83 1.07 3.60 4.55 10.58 1.10
201_t1 0.68 0.95 26.40 1.24 0.61 4.97 2.42 8.18 0.79
27_t0 0.93 1.27 11.55 0.92 0.79 6.63 5.94 9.94 0.85
27_t1 1.50 1.20 5.73 1.17 1.08 6.96 6.71 16.05 0.98
28_t0 1.01 1.25 10.87 1.30 1.25 8.09 3.21 9.18 1.16
28_t1 4.13 0.83 3.48 0.71 0.72 15.51 3.62 21.80 0.72
31_t0 0.86 1.79 8.95 0.90 0.60 3.97 9.44 11.95 0.79
31_t1 1.49 1.61 13.21 0.73 0.29 3.70 5.92 2.23 0.32
32_t0 1.50 0.93 3.41 0.82 0.60 9.19 4.91 29.78 0.67
32_t1 1.10 1.23 8.22 0.86 0.55 6.54 9.01 26.57 0.79
33_t0 1.97 1.30 5.08 1.02 0.83 6.69 1.70 23.17 1.03
33_t1 0.72 0.78 4.37 0.61 0.76 12.08 2.04 30.09 0.54
34_t0 3.10 0.80 14.86 1.01 0.68 10.06 4.34 14.17 0.86
34_t1 2.53 0.96 10.55 1.08 0.69 6.41 3.51 12.91 0.66
35_t0 1.07 0.98 4.18 1.22 0.75 4.80 3.44 23.53 0.82
35_t1 3.19 0.71 2.02 0.90 0.68 5.75 4.09 21.93 0.88
37_t0 0.39 0.85 17.57 0.62 0.35 6.79 5.79 26.82 0.37
37_t1 0.82 0.56 9.37 0.52 0.58 12.29 2.73 32.73 0.41
59_t0 0.41 3.68 12.58 0.52 0.18 6.42 11.54 7.68 0.25
59_t1 1.03 1.39 6.64 0.88 0.57 13.60 5.20 22.80 0.59
63_t0 2.14 2.39 6.37 1.62 0.60 12.73 6.15 11.50 0.64
63_t1 1.79 1.01 6.89 5.28 0.31 8.22 2.22 18.11 1.74
65_t0 1.39 0.68 14.29 0.56 0.40 6.13 2.45 21.46 0.42
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10 11 12 13 14 15 16 17 18
65_t1 1.27 0.91 3.53 1.54 0.91 4.52 2.37 15.05 1.01
66_t0 2.06 1.89 10.59 0.46 0.16 2.98 3.52 9.37 0.17
66_t1 1.39 1.81 9.67 1.72 1.17 2.74 4.26 14.12 1.48
78_t0 0.96 3.15 11.45 0.69 0.62 5.90 15.45 9.60 0.63
78_t1 1.80 1.66 5.16 1.85 1.71 6.75 2.08 15.74 2.25
80_t0 0.44 2.96 7.77 0.49 0.16 3.68 8.01 7.59 0.18
80_t1 1.82 0.75 10.63 0.75 0.53 2.71 2.38 15.10 0.64
82_t0 1.26 1.47 6.91 1.57 1.34 3.09 2.02 14.89 1.23
82_t1 0.99 1.11 1.72 1.40 1.32 3.92 4.06 18.63 1.05
83_t0 0.92 0.75 6.31 1.20 0.44 8.17 3.59 9.91 0.84
83_t1 7.72 1.58 11.71 0.97 0.40 3.14 3.12 20.22 0.32
84_t0 5.06 1.56 7.49 0.89 0.55 10.80 10.13 20.41 0.68
84_t1 4.40 1.65 8.68 1.18 0.94 8.90 7.45 17.55 1.05
89_t0 0.62 0.61 1.55 0.70 0.69 3.99 1.32 35.18 0.64
89_t1 1.36 1.50 4.53 1.64 1.37 3.60 10.86 9.37 1.64
19 20 21 22 23 24 25 26 27
201_t0 3.57 1.59 11.24 1.83 1.07 3.60 4.55 10.58 1.10
201_t1 0.68 0.95 26.40 1.24 0.61 4.97 2.42 8.18 0.79
27_t0 0.93 1.27 11.55 0.92 0.79 6.63 5.94 9.94 0.85
27_t1 1.50 1.20 5.73 1.17 1.08 6.96 6.71 16.05 0.98
28_t0 1.01 1.25 10.87 1.30 1.25 8.09 3.21 9.18 1.16
28_t1 4.13 0.83 3.48 0.71 0.72 15.51 3.62 21.80 0.72
31_t0 0.86 1.79 8.95 0.90 0.60 3.97 9.44 11.95 0.79
31_t1 1.49 1.61 13.21 0.73 0.29 3.70 5.92 2.23 0.32
32_t0 1.50 0.93 3.41 0.82 0.60 9.19 4.91 29.78 0.67
32_t1 1.10 1.23 8.22 0.86 0.55 6.54 9.01 26.57 0.79
33_t0 1.97 1.30 5.08 1.02 0.83 6.69 1.70 23.17 1.03
33_t1 0.72 0.78 4.37 0.61 0.76 12.08 2.04 30.09 0.54
34_t0 3.10 0.80 14.86 1.01 0.68 10.06 4.34 14.17 0.86
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19 20 21 22 23 24 25 26 27
34_t1 2.53 0.96 10.55 1.08 0.69 6.41 3.51 12.91 0.66
35_t0 1.07 0.98 4.18 1.22 0.75 4.80 3.44 23.53 0.82
35_t1 3.19 0.71 2.02 0.90 0.68 5.75 4.09 21.93 0.88
37_t0 0.39 0.85 17.57 0.62 0.35 6.79 5.79 26.82 0.37
37_t1 0.82 0.56 9.37 0.52 0.58 12.29 2.73 32.73 0.41
59_t0 0.41 3.68 12.58 0.52 0.18 6.42 11.54 7.68 0.25
59_t1 1.03 1.39 6.64 0.88 0.57 13.60 5.20 22.80 0.59
63_t0 2.14 2.39 6.37 1.62 0.60 12.73 6.15 11.50 0.64
63_t1 1.79 1.01 6.89 5.28 0.31 8.22 2.22 18.11 1.74
65_t0 1.39 0.68 14.29 0.56 0.40 6.13 2.45 21.46 0.42
65_t1 1.27 0.91 3.53 1.54 0.91 4.52 2.37 15.05 1.01
66_t0 2.06 1.89 10.59 0.46 0.16 2.98 3.52 9.37 0.17
66_t1 1.39 1.81 9.67 1.72 1.17 2.74 4.26 14.12 1.48
78_t0 0.96 3.15 11.45 0.69 0.62 5.90 15.45 9.60 0.63
78_t1 1.80 1.66 5.16 1.85 1.71 6.75 2.08 15.74 2.25
80_t0 0.44 2.96 7.77 0.49 0.16 3.68 8.01 7.59 0.18
80_t1 1.82 0.75 10.63 0.75 0.53 2.71 2.38 15.10 0.64
82_t0 1.26 1.47 6.91 1.57 1.34 3.09 2.02 14.89 1.23
82_t1 0.99 1.11 1.72 1.40 1.32 3.92 4.06 18.63 1.05
83_t0 0.92 0.75 6.31 1.20 0.44 8.17 3.59 9.91 0.84
83_t1 7.72 1.58 11.71 0.97 0.40 3.14 3.12 20.22 0.32
84_t0 5.06 1.56 7.49 0.89 0.55 10.80 10.13 20.41 0.68
84_t1 4.40 1.65 8.68 1.18 0.94 8.90 7.45 17.55 1.05
89_t0 0.62 0.61 1.55 0.70 0.69 3.99 1.32 35.18 0.64
89_t1 1.36 1.50 4.53 1.64 1.37 3.60 10.86 9.37 1.64
28 29 30 31 32 33 34
201_t0 3.80 7.14 1.38 1.32 2.11 1.11 1.20
201_t1 6.48 10.42 0.93 0.65 1.18 0.76 1.00
27_t0 2.39 16.49 1.00 1.15 0.96 0.96 1.01
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28 29 30 31 32 33 34
27_t1 2.53 17.99 1.22 2.27 1.35 1.08 1.38
28_t0 2.08 22.86 1.51 1.90 1.43 1.29 1.42
28_t1 2.62 13.66 0.73 1.26 1.27 0.80 1.25
31_t0 3.03 9.34 2.91 0.58 2.22 0.71 0.87
31_t1 2.60 4.43 0.65 0.29 3.17 0.30 2.88
32_t0 1.20 17.53 1.06 0.82 1.13 0.63 0.80
32_t1 1.69 13.54 0.89 0.83 2.25 0.58 0.77
33_t0 3.40 21.85 1.53 1.14 0.99 0.81 0.89
33_t1 4.73 19.77 0.77 1.53 1.00 0.99 0.52
34_t0 7.68 1.53 0.83 0.87 3.51 1.12 0.89
34_t1 9.71 7.57 1.35 1.19 1.28 0.89 1.14
35_t0 1.57 22.55 1.13 3.06 0.92 0.84 1.38
35_t1 1.57 24.34 0.98 3.92 1.04 0.70 0.85
37_t0 2.02 14.57 1.14 6.27 1.28 0.38 0.44
37_t1 1.65 16.30 1.38 1.95 1.22 0.41 0.51
59_t0 8.10 6.58 1.03 0.34 6.04 0.34 1.42
59_t1 4.75 12.90 1.12 1.64 1.74 0.65 0.64
63_t0 1.91 15.24 0.41 1.66 0.92 6.41 1.12
63_t1 3.16 4.63 0.79 4.13 3.80 0.50 0.72
65_t0 3.10 24.28 2.82 1.61 0.84 0.55 0.45
65_t1 1.95 33.97 1.48 1.35 1.15 0.86 0.83
66_t0 5.88 16.97 3.28 1.00 2.82 0.45 1.80
66_t1 3.74 8.34 1.64 1.64 3.03 1.79 1.40
78_t0 7.58 4.12 0.72 0.59 8.38 0.64 0.73
78_t1 3.24 7.82 1.75 1.61 2.00 1.97 1.66
80_t0 4.74 7.05 2.25 0.24 7.26 0.25 1.48
80_t1 4.20 19.10 0.72 1.02 3.66 0.68 0.85
82_t0 5.05 14.48 2.67 1.54 1.52 1.66 1.31
82_t1 2.35 22.55 1.51 1.11 1.19 4.55 0.99
83_t0 7.24 21.72 0.57 2.79 2.13 0.64 3.28
143
28 29 30 31 32 33 34
83_t1 4.64 4.47 0.43 4.01 2.85 0.66 3.45
84_t0 2.39 1.38 0.79 1.60 2.22 0.77 0.99
84_t1 2.16 2.07 1.22 1.83 2.80 0.96 1.08
89_t0 0.67 30.36 0.83 3.43 0.62 0.82 0.77
89_t1 2.24 10.52 1.46 1.18 2.03 4.44 1.39
Healthy subjects for comparative study:
1 2 3 4 5 6 7 8 9
HS1 0.2521 0.3476 1.7689 0.3321 0.1684 0.9519 0.7811 0.7292 0.1893
HS2 0.2497 0.8499 1.8122 0.3317 0.2029 1.5475 2.1279 0.259 0.1432
HS3 0.1481 0.2367 2.641 0.463 0.1004 0.977 3.7271 0.3177 0.12
HS4 0.5366 0.7253 0.4023 0.282 0.5489 0.3508 0.3071 0.3183 0.2967
HS5 0.361 0.3554 1.2503 0.2259 0.1812 0.6889 0.3366 0.2928 0.1719
HS6 0.6199 1.1297 0.7183 0.4699 0.4301 1.0287 1.6489 0.5683 0.4683
HS7 0.2165 0.3803 2.8645 0.2875 0.1758 0.4595 1.7546 0.218 0.2022
HS8 0.5103 1.9707 1.409 0.4938 0.3579 0.5426 1.5386 0.5449 0.3182
HS9 0.8328 2.092 1.3674 1.8255 0.6051 0.8673 1.909 0.59 0.6399
HS10 0.502 0.776 1.6018 0.3275 0.227 1.07 2.0915 0.4672 0.2516
HS11 0.2895 0.4331 0.3081 1.0653 0.325 1.0696 0.6626 0.2885 0.4387
HS12 0.391 0.4995 1.4856 0.2112 0.3192 1.5638 1.1797 0.6707 0.2383
HS13 0.6208 1.2139 1.198 0.5039 0.4577 1.1782 0.6271 0.5502 0.7499
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1 2 3 4 5 6 7 8 9
HS14 0.3324 0.8668 1.6517 0.3004 0.1995 0.8103 1.7092 0.3974 0.2735
HS15 0.2994 0.8356 0.7249 0.3 0.224 1.338 0.7324 0.402 0.2622
HS16 0.2871 0.2741 1.0933 0.1752 0.1337 1.9443 1.3313 0.4646 0.0997
HS17 0.2413 0.4346 0.9704 0.2094 0.1482 0.4151 0.3109 0.4107 0.1789
HS18 0.2954 0.5917 0.5008 0.1716 0.1739 0.3342 1.066 0.2559 0.23
HS19 0.8889 0.793 0.5666 0.3625 0.2789 0.6211 0.3928 0.7 0.3588
HS20 0.6405 0.8843 0.5672 0.3369 0.4888 0.5861 0.3193 0.38 0.3424
HS21 0.3237 0.619 0.8644 0.404 0.2327 0.6395 0.3139 0.4742 0.2664
HS22 0.2032 0.3795 2.1908 0.7713 0.419 0.3313 1.7752 0.3488 0.1677
HS23 0.6205 0.6325 0.3997 0.2381 0.2703 0.3913 0.4049 0.4849 0.294
HS24 0.6155 0.8252 0.5691 0.3075 0.3784 0.4741 0.3637 0.4922 0.5639
10 11 12 13 14 15 16 17 18
HS1 0.406 2.5407 21.399 0.7386 0.1637 2.3453 15.975 7.2115 0.7691
HS2 0.4094 3.6887 25.529 0.5557 0.5536 2.409 7.3833 3.177 0.1811
HS3 0.2192 1.4882 13.812 0.4257 0.0976 2.1137 23.282 4.1006 0.1573
HS4 0.6393 0.6868 26.183 0.5543 0.2832 2.7427 1.0824 22.523 0.4247
HS5 0.4518 1.8647 19.933 0.5085 0.1812 1.9736 15.647 12.007 0.2114
HS6 0.8317 1.1987 35.3 0.7597 0.4414 2.1454 4.661 6.0275 0.5392
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10 11 12 13 14 15 16 17 18
HS7 0.3502 0.7964 11.414 0.4492 0.2727 1.1521 32.629 5.4433 0.1791
HS8 0.5457 1.6318 32.131 0.5694 0.1867 2.8843 4.739 14.405 0.3275
HS9 2.7625 1.0323 20.228 2.05 2.4394 2.5246 2.1549 12.464 1.9064
HS10 0.374 3.2136 24.126 0.7056 0.2772 3.0256 12.323 5.6171 0.2437
HS11 0.7427 1.0226 2.4654 0.5245 0.7797 14.147 3.7081 19.803 0.2194
HS12 1.8617 1.8946 8.9693 0.5047 0.3001 3.6787 8.0279 7.6682 0.3024
HS13 0.5078 1.4213 25.608 1.53 0.3695 3.4775 6.6021 13.326 0.4939
HS14 0.4438 2.9676 24.328 0.7337 0.2421 2.9674 13.171 6.914 0.2542
HS15 0.9126 1.3143 9.2998 0.7568 0.2538 12.246 7.2053 20.44 0.2803
HS16 1.7545 2.3931 15.481 0.5456 0.1038 5.8428 12.04 8.3541 0.1975
HS17 0.5099 1.4528 21.249 0.5546 0.1865 2.4566 18.202 13.35 0.2003
HS18 0.3614 0.5274 10.663 0.6747 0.1868 1.6567 45.246 5.9097 0.1852
HS19 0.506 1.1394 29.805 0.7977 0.3654 4.0422 4.8995 17.575 0.3516
HS20 0.6299 0.9753 26.474 0.9464 0.253 2.9776 6.6293 17.721 1.1107
HS21 0.5828 1.3038 19.343 0.7011 0.2616 2.6031 20.873 14.313 0.2576
HS22 0.2457 1.086 10.411 0.5143 0.1418 1.6264 41.146 4.2271 0.3057
HS23 0.6236 0.9823 29.378 0.7208 0.2242 4.0409 5.5988 17.761 0.2857
HS24 0.6203 1.6284 30.902 0.9004 0.2592 3.2791 7.3661 12.812 0.5389
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19 20 21 22 23 24 25 26 27
HS1 0.2537 0.2443 8.0839 1.9839 4.2084 0.2174 0.2624 5.6287 1.0538
HS2 0.2141 0.5139 9.5881 3.6509 8.3965 0.8214 0.2799 3.6918 4.044
HS3 0.1299 0.184 9.0344 1.4048 6.2385 0.168 0.1814 9.4537 0.9364
HS4 0.523 0.3593 1.4043 0.6577 1.7167 0.5721 1.7468 5.6698 2.5911
HS5 0.2843 0.3557 5.5402 1.6529 3.5693 0.3094 0.3489 6.9275 1.4187
HS6 0.7789 0.597 6.4987 1.5355 2.8471 1.2536 0.5445 1.1895 3.6281
HS7 0.1951 0.449 6.4494 1.1473 4.0956 0.2473 0.2079 11.084 0.9354
HS8 0.3925 0.2782 3.484 0.5802 2.0265 0.6297 0.4355 3.678 2.0173
HS9 0.7739 1.9068 3.565 1.0171 1.7422 2.1033 0.6909 1.4832 5.9189
HS10 0.4998 0.4865 9.1618 3.2401 4.7489 1.1163 0.4055 2.4861 4.6008
HS11 2.499 1.3053 2.863 0.754 3.8199 3.6089 2.4525 1.4023 1.4299
HS12 1.5311 0.2556 6.0289 4.665 7.8084 0.4348 0.4059 5.1036 0.8376
HS13 0.4587 0.4328 4.7667 1.1298 3.7577 1.2639 0.4955 1.5559 4.9212
HS14 0.3008 0.4037 8.6543 3.0806 4.1709 1.139 0.3224 2.4177 4.4624
HS15 0.5975 0.311 4.0307 1.0914 2.7062 0.5315 0.5375 2.9034 0.8112
HS16 0.1296 0.1347 9.3251 3.9004 5.3727 0.24 0.2993 2.7654 0.6537
HS17 0.4281 0.2115 4.5582 1.0694 2.5029 0.3673 0.2491 5.5642 1.3994
HS18 0.2751 0.296 4.0184 0.8811 0.7889 0.4404 0.4497 9.2985 1.376
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19 20 21 22 23 24 25 26 27
HS19 0.5617 0.3257 3.7717 0.5721 1.388 0.5417 0.4059 6.2007 2.3785
HS20 0.4794 1.0026 3.9807 0.7132 0.742 1.6297 0.4478 0.7457 4.9458
HS21 0.3432 0.2728 3.9736 0.946 1.9626 0.3839 0.3444 5.3697 1.5598
HS22 0.2129 0.236 5.8925 1.3306 3.7417 0.3596 0.2048 8.491 0.9902
HS23 0.4352 0.2754 3.3818 0.5982 1.2855 0.5284 0.3557 6.517 2.3443
HS24 0.481 0.298 3.3627 0.7797 1.8908 2.1207 0.4536 0.8676 4.6866
28 29 30 31 32 33 34
HS1 4.150179 9.278325 0.82764 1.882997 0.548024 0.234012 0.27025
HS2 3.869892 4.931696 2.478049 0.4344 0.669452 0.256973 0.294333
HS3 2.111133 5.44756 1.637268 3.20485 0.658592 0.202208 0.13701
HS4 0.784369 15.13325 3.330237 2.836168 0.474948 0.377409 0.402132
HS5 3.510455 12.15612 0.970873 3.083745 0.453074 0.090299 0.252901
HS6 2.436507 5.910112 4.612751 1.130444 0.887057 0.534239 0.638397
HS7 1.328906 6.969357 1.37832 2.323454 0.392552 0.220732 0.240548
HS8 1.029425 11.40181 3.395659 2.548808 0.481189 0.12971 0.277728
HS9 2.897009 8.057857 3.426319 1.795201 1.501705 0.443831 0.839544
HS10 2.978875 4.712036 3.139784 0.536465 0.627043 0.376926 0.365966
HS11 1.703096 20.63053 0.274607 0.8626 1.045756 2.789146 0.946347
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28 29 30 31 32 33 34
HS12 7.388228 11.46457 0.763486 0.800529 2.490298 0.448324 1.229064
HS13 2.585649 8.435593 2.964544 1.891725 0.832984 0.856676 0.671091
HS14 3.170746 4.879374 3.023485 0.48939 0.420601 0.287663 0.524289
HS15 2.689284 19.70278 0.401608 0.877934 1.162587 0.29218 0.288695
HS16 5.008319 11.8164 0.603528 0.566201 1.690401 0.151447 0.181522
HS17 3.734015 11.4004 0.90549 3.20276 0.364324 0.17914 0.189535
HS18 0.926931 6.858228 0.563526 1.518335 0.273798 0.275126 0.224017
HS19 1.122669 10.4729 2.700028 2.123529 0.441868 0.335099 0.313154
HS20 2.328325 10.67527 4.318832 2.497872 0.43233 0.460428 0.352506
HS21 3.37187 10.46361 0.970274 2.687751 0.443748 0.27732 0.286154
HS22 1.381211 5.683368 0.814678 1.928098 0.391056 0.431337 0.153139
HS23 1.306624 11.50628 2.614276 2.401733 0.427142 0.299445 0.318814
HS24 2.551476 9.608119 4.708712 2.358174 0.310065 0.360346 0.321425
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Annex 4. Bacterial groups detected by FISH in the culture broth recovered from each 
stage (Vessel 1, Vessel 2 and Vessel 3) of the colonic model before (SS1) and after 
(SS2) the daily administration of the four dietary flours.
Modifications at a confidence level of 95% (P < 0.05) are represented as underlined or italic 
in case of significant increase or decrease, respectively, between SS1 and SS2.
Nutriwheat (NW)
SS1 SS2
Vessel 1 Vessel 2 Vessel 3 Vessel 1 Vessel 2 Vessel 3
FPrau655 8.79 ± 0.07 8.82 ± 0.11 8.46 ± 0.11 8.66 ± 0.13 8.11 ± 0.16 7.75 ± 0.13
Bif164 7.38 ± 0.11 7.26 ± 0.16 7.28 ± 0.14 7.70 ± 0.04 7.61 ± 0.14 7.45 ± 0.08
Lab158 7.70 ± 0.16 7.79 ± 0.18 7.85 ± 0.17 8.23 ± 0.26 7.97 ± 0.18 7.72 ± 0.08
Ere432 8.67 ± 0.09 8.71 ± 0.07 8.58 ± 0.11 8.71 ± 0.13 8.70 ± 0.15 8.56 ± 0.10
Ato291 8.63 ± 0.12 8.53 ± 0.13 8.42 ± 0.12 8.69 ± 0.08 8.63 ± 0.12 8.39 ± 0.17
Rre534 7.99 ± 0.21 7.77 ± 0.07 7.87 ± 0.07 7.91 ± 0.28 7.57 ± 0.15 7.51 ± 0.16
EUB338 9.75 ± 0.12 9.49 ± 0.07 9.38 ± 0.09 9.57 ± 0.07 9.43 ± 0.10 9.05 ± 0.06
Bac303 8.58 ± 0.26 8.94 ± 0.07 8.41 ± 0.19 8.79 ± 0.22 8.94 ± 0.21 8.82 ± 0.11
RbroRfla 8.92 ± 0.06 8.55 ± 0.19 8.30 ± 0.11 8.38 ± 0.15 7.87 ± 0.08 7.53 ± 0.09
DSV567 6.49 ± 0.43 7.03 ± 0.39 6.45 ± 0.29 7.22 ± 0.16 7.50 ± 0.17 7.83 ± 0.27
Prop853 8.97 ± 0.14 8.79 ± 0.13 8.60 ± 0.11 8.82 ± 0.09 8.76 ± 0.13 8.65 ±0.08
Chis150 8.21 ± 0.09 8.13 ± 0.16 7.93 ± 0.23 8.15 ± 0.24 7.66 ± 0.31 7.67 ± 0.35
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Wholegrain Rye (WG)
SS1 SS2
Vessel 1 Vessel 2 Vessel 3 Vessel 1 Vessel 2 Vessel 3
FPrau655 8.71 ± 0.09 8.58 ± 0.07 8.24 ± 0.13 8.36 ± 0.38 8.63 ± 0.14 8.61 ± 0.15
Bif164 7.46 ± 0.13 7.30 ± 0.12 7.26 ± 0.14 8.54 ± 0.23 8.65 ± 0.22 8.71 ± 0.25
Lab158 7.81  ± 0.29 7.64  ± 0.24 7.73 ± 0.19 8.56 ± 0.19 8.73 ±0.23 8.52 ± 0.23
Ere432 8.68 ± 0.11 8.80 ± 0.10 8.60 ± 0.14 8.04 ± 0.38 8.84 ± 0.15 8.83 ± 0.13
Ato291 8.58 ± 0.17 8.50 ± 0.13 8.55 ± 0.13 8.88 ± 0.12 8.77 ± 0.11 8.72 ± 0.13
Rre534 7.88 ± 0.17 7.91 ± 0.14 7.70 ± 0.21 7.26 ± 0.22 7.77 ± 0.16 7.64 ± 0.08
EUB338 9.67 ± 0.08 9.41 ± 0.06 9.17 ± 0.17 9.61 ± 0.15 9.55 ± 0.07 9.43 ± 0.09
Bac303 8.64 ± 0.27 8.92 ± 0.17 8.60 ± 0.16 8.78 ± 0.24 9.14 ± 0.09 8.85 ± 0.11
RbroRfla 8.53 ± 0.21 8.44 ± 0.16 8.28 ± 0.18 8.29 ± 0.25 8.34 ± 0.15 7.94 ± 0.08
DSV567 6.61 ± 0.40 6.66 ± 0.26 6.65 ± 0.15 7.38 ± 0.37 7.49 ± 0.29 7.78 ± 0.28
Prop853 8.80 ± 0.15 8.73 ± 0.12 8.73 ± 0.15 8.80 ± 0.17 8.95 ± 0.08 8.74 ± 0.11
Chis150 8.18 ± 0.12 8.20 ± 0.09 8.21 ± 0.17 7.27 ± 0.37 8.35 ± 0.28 8.40 ± 0.20
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Barley milled grains (BMG)
SS1 SS2
Vessel 1 Vessel 2 Vessel 3 Vessel 1 Vessel 2 Vessel 3
FPrau655 8.96 ± 0.15 8.79 ± 0.17 8.68 ± 0.12 8.79 ± 0.28 8.70 ± 0.06 8.44 ± 0.05
Bif164 8.72 ± 0.09 8.65 ± 0.07 8.52 ±0.08 8.74 ± 0.50 8.96 ±0.11 8.67 ±0.26
Lab158 8.82 ± 0.07 8.68 ± 0.07 8.52 ± 0.05 8.63 ± 0.14 8.67 ± 0.04 8.50 ± 0.03
Ere432 8.96 ± 0.09 8.88 ± 0.17 8.94 ± 0.06 8.58 ± 0.29 8.80 ± 0.06 8.75 ± 0.06
Ato291 8.72 ± 0.04 8.82 ± 0.03 8.83 ± 0.02 8.87 ± 0.08 8.72 ± 0.07 8.60 ± 0.09
Rre534 8.30 ± 0.16 8.12 ± 0.08 8.14 ± 0.13 7.82 ± 0.38 7.77 ± 0.15 7.39 ± 0.10
EUB338 9.38 ± 0.44 9.66 ± 0.15 9.25 ± 0.10 9.51 ± 0.17 9.37 ± 0.11 9.23 ± 0.12
Bac303 8.34 ± 0.29 8.59 ± 0.13 8.47 ±0.17 8.69 ± 0.25 8.93 ± 0.09 8.47 ±0.14
RbroRfla 7.93 ± 0.40 8.65 ± 0.11 8.50 ± 0.18 7.64 ± 0.63 7.59 ± 0.60 8.33 ± 0.09
DSV567 6.77 ± 0.11 6.87 ± 0.09 7.04 ± 0.09 7.41 ± 0.19 7.63 ± 0.18 7.54 ± 0.21
Prop853 8.65 ± 0.16 8.80 ± 0.12 8.80 ± 0.13 8.80 ± 0.05 8.81 ±0.09 8.56 ±0.09
Chis150 8.53 ± 0.07 8.57 ± 0.10 8.44 ± 0.14 8.36 ± 0.17 8.64 ± 0.08 8.49 ± 0.15
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Pulses (PF)
SS1 SS2
Vessel 1 Vessel 2 Vessel 3 Vessel 1 Vessel 2 Vessel 3
FPrau655 8.86 ± 0.09 8.75 ± 0.08 8.65 ± 0.13 8.93 ± 0.06 8.50 ± 0.05 8.19 ± 0.08
Bif164 8.05 ± 0.45 8.57 ± 0.08 8.25 ± 0.13 8.41 ± 0.19 8.89 ± 0.19 8.78 ± 0.08
Lab158 8.73 ± 0.09 8.63 ± 0.07 8.46 ± 0.14 8.64 ±0.04 8.61 ± 0.04 8.48 ± 0.05
Ere432 8.99 ± 0.06 8.94 ±0.06 8.86 ± 0.11 8.60 ±0.04 8.77 ± 0.05 8.70 ± 0.05
Ato291 8.74 ± 0.05 8.79 ± 0.06 8.76 ± 0.06 8.87 ± 0.03 8.93 ±0.09 8.80 ±0.06
Rre534 8.61 ± 0.13 8.23 ±0.11 8.06 ± 0.14 7.52 ± 0.32 7.55 ± 0.14 7.46 ± 0.19
EUB338 9.67 ± 0.11 9.26 ±0.08 9.26 ± 0.12 9.76 ± 0.07 9.48 ± 0.12 9.35 ± 0.07
Bac303 8.32 ± 0.41 8.63 ±0.13 8.53 ± 0.19 9.45 ± 0.04 9.09 ± 0.05 8.95 ± 0.07
RbroRfla 7.50 ± 0.55 8.39 ± 0.11 8.18 ± 0.11 6.25 ± 0.05 8.50 ± 0.06 8.51 ± 0.07
DSV567 7.38 ± 0.32 7.36 ± 0.27 6.88 ±0.44 7.12 ± 0.38 6.89 ± 0.35 6.72 ± 0.34
Prop853 8.79 ±0.10 8.83 ± 0.09 8.66 ±0.04 8.79 ±0.05 8.64 ± 0.04 8.55 ±0.05
Chis150 8.60 ± 0.08 8.21 ± 0.11 8.14 ±0.13 8.19±0.15 8.41 ±0.08 8.47± 0.09
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